{"gene":"ARID1A","run_date":"2026-06-09T22:02:44","timeline":{"discoveries":[{"year":1998,"finding":"ARID1A (p270) is an integral component of human SWI/SNF chromatin remodeling complexes, co-purifying with SWI/SNF subunits via antibodies raised against p300/CBP.","method":"Immunoprecipitation and protein purification from mammalian cells","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal co-purification established complex membership, replicated by subsequent structural and biochemical studies across multiple labs","pmids":["9584200"],"is_preprint":false},{"year":2000,"finding":"ARID1A (p270) contains an ARID (AT-rich interactive domain) DNA-binding motif but, unlike other ARID family members, shows no sequence-specific DNA binding preference, demonstrating that AT-rich binding is not an intrinsic property of all ARID domains.","method":"DNA binding assays (in vitro) with purified ARID domain","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct in vitro biochemical assay with purified protein; negative result (no sequence preference) is mechanistically informative and well-controlled","pmids":["10757798"],"is_preprint":false},{"year":2005,"finding":"ARID1A (p270) is specifically required for cell cycle arrest upon differentiation induction: siRNA depletion of p270 (but not the related ARID1B) causes continued DNA synthesis, failure to upregulate p21, and failure to downregulate cyclins and E2F-responsive products, demonstrating a distinct anti-proliferative role for p270-containing SWI/SNF complexes.","method":"siRNA knockdown, DNA synthesis assay, Western blot for p21 and cyclins in differentiation-inducible cell system","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean loss-of-function with specific cellular phenotype, isoform-specificity established by parallel ARID1B knockdown control, two orthogonal readouts","pmids":["16230384"],"is_preprint":false},{"year":2008,"finding":"BAF250a (ARID1A) is essential for early mouse embryonic germ-layer formation (mesodermal layer) and embryonic stem cell pluripotency and self-renewal; ablation arrests development at ~E6.5, promotes primitive endoderm differentiation, and impairs cardiomyocyte and adipocyte but not neuron differentiation, correlating with altered expression of Sox2, Utf1, and Oct4.","method":"Mouse knockout (conditional ablation), DNA microarray, immunostaining, RNA analysis, embryoid body differentiation assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo genetic knockout with defined developmental phenotype, multiple orthogonal methods confirming molecular mechanism","pmids":["18448678"],"is_preprint":false},{"year":2010,"finding":"BAF250b (the ARID1B paralog) assembles with elongin C, cullin 2, and Roc1 into an E3 ubiquitin ligase that monoubiquitinates histone H2B at lysine 120 in vitro; RNAi depletion of BAF250 in human cells and mutation of Drosophila osa (its ortholog) reduce global H2B monoubiquitination, adding an enzymatic ubiquitin ligase function to SWI/SNF-A. Note: this study primarily characterizes ARID1B but also implicates BAF250/ARID1 family members in H2B ubiquitination.","method":"Immunopurification, in vitro ubiquitination assay, RNAi in human cells, Drosophila genetics","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution of E3 ligase activity toward H2B-K120; primary characterization is ARID1B, but ARID1A family implication is demonstrated by RNAi of shared subunit; single lab","pmids":["20086098"],"is_preprint":false},{"year":2009,"finding":"ARID1A physically interacts with the tumor suppressor HIC1 in a BRG1-dependent manner; sequential ChIP demonstrated that HIC1 recruits ARID1A-containing SWI/SNF complexes to repress E2F1 transcription in quiescent fibroblasts; HIC1 does not interact with BRM-containing complexes, establishing specificity for ARID1A-SWI/SNF.","method":"Yeast two-hybrid, co-immunoprecipitation, sequential ChIP-reChIP in WI38 fibroblasts and BRG1-null SW13 cells","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal co-IP plus ChIP-reChIP functional validation; interaction dependency confirmed in BRG1-null cells; multiple orthogonal methods in single lab","pmids":["19486893"],"is_preprint":false},{"year":2012,"finding":"BAF250a (ARID1A) regulates cardiac progenitor cell differentiation in the second heart field by binding selectively to target gene promoters (Mef2c, Nkx2.5, Bmp10) and recruiting the catalytic subunit Brg1 to modulate chromatin accessibility; ablation in SHF causes right ventricular trabeculation defects, VSD, persistent truncus arteriosus, and embryonic lethality.","method":"Conditional mouse knockout, ChIP, DNase I digestion (chromatin accessibility), ES cell differentiation model, immunostaining","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo conditional KO with defined cardiac phenotype, ChIP demonstrating direct promoter binding and Brg1 recruitment, chromatin accessibility assay; multiple orthogonal methods","pmids":["22621927"],"is_preprint":false},{"year":2013,"finding":"BAF250a physically interacts with NuRD complex subunits and cooperates with NuRD to repress cardiac gene transcription by switching chromatin between open and poised states; specific depletion of BAF250a in P19 cells causes arrhythmic contracting cardiomyocytes and modulates BRG1 occupancy at cardiac gene loci.","method":"Affinity purification coupled to mass spectrometry, co-immunoprecipitation, ChIP, RNA knockdown in P19 cells and embryonic heart","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mass spectrometry-based complex identification plus ChIP functional validation; single lab, multiple orthogonal methods","pmids":["24335282"],"is_preprint":false},{"year":2014,"finding":"Baf250a (ARID1A) maintains sinoatrial node (SAN) pacemaker cell identity by activating Tbx3 expression and, together with Tbx3 and HDAC3, coordinately repressing Nkx2.5; SAN-specific deletion causes sinus bradycardia and sick sinus disease by derepressing Nkx2.5-driven contractile cardiomyocyte gene program.","method":"Conditional mouse knockout (SAN-specific), transcriptomic time-series analysis, genetic epistasis","journal":"Cell research","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo conditional KO with defined arrhythmia phenotype, transcriptional hierarchy established by time-series gene expression, genetic pathway ordering","pmids":["25145359"],"is_preprint":false},{"year":2015,"finding":"BAF250a (ARID1A) regulates nucleosome occupancy at bivalent (H3K4me3/H3K27me3) promoters of key developmental genes in embryonic stem cells; acute deletion increases nucleosome occupancy at these promoters, reduces H3K27me3 and bivalent gene number, elevates Brg1 but reduces Suz12 recruitment, and disrupts differentiation timing.","method":"Acute conditional deletion, genome-wide nucleosome mapping (MNase-seq), histone modification ChIP-seq, gene expression analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — genome-wide nucleosome and histone modification profiling with direct genetic perturbation; multiple orthogonal epigenomic methods in single lab","pmids":["26070559"],"is_preprint":false},{"year":2015,"finding":"EZH2 inhibition is synthetically lethal in ARID1A-mutated ovarian cancer cells; ARID1A and EZH2 co-occupy and regulate PIK3IP1, a direct target whose upregulation upon EZH2 inhibition suppresses PI3K-AKT signaling and mediates the synthetic lethality; EZH2 inhibition causes in vivo regression of ARID1A-mutated tumors.","method":"Cell viability assays, ChIP, gene expression analysis, mouse xenograft models, PI3K-AKT signaling assays","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — mechanistic pathway placement (ARID1A–EZH2–PIK3IP1–PI3K-AKT) with ChIP evidence for co-occupancy, validated in vivo; replicated by subsequent studies","pmids":["25686104"],"is_preprint":false},{"year":2019,"finding":"ARID1A-mediated chromatin remodeling is required for expression of SLC7A11, a cystine transporter; ARID1A deficiency reduces basal glutathione (GSH) levels by impairing SLC7A11 expression, making ARID1A-deficient cells specifically vulnerable to GCLC inhibition through ROS-mediated apoptosis.","method":"ARID1A knockout cell lines, glutathione measurement, ROS assays, apoptosis assays, xenograft models, ChIP for SLC7A11 locus","journal":"Cancer cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — loss-of-function with defined metabolic mechanism (SLC7A11-GSH axis), in vivo validation; multiple orthogonal methods","pmids":["30686770"],"is_preprint":false},{"year":2019,"finding":"ARID1A inactivation causes defects in telomere cohesion by reducing expression of cohesin subunit STAG1; this selectively eliminates cells with gross chromosomal aberrations during mitosis, explaining why ARID1A-mutated tumors paradoxically lack copy number alterations.","method":"ARID1A knockout, telomere FISH, colony formation assays, ChIP for STAG1 locus, STAG1 rescue experiments, analysis of copy number alterations in cancer genomics data","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic loss-of-function, rescue by STAG1 re-expression, mechanistic link to telomere cohesion established, corroborated by cancer genomics data","pmids":["31492885"],"is_preprint":false},{"year":2019,"finding":"ARID1A spatially partitions interphase chromosomes by interacting with condensin II; ARID1A knockout drives redistribution of condensin II preferentially to enhancers, contributes to B-compartment formation, weakens TAD borders, and increases trans interactions of small chromosomes.","method":"Co-immunoprecipitation (SWI/SNF–condensin II interaction), Hi-C, ChIP-seq, 3D interphase chromosome painting, ARID1A knockout cells","journal":"Science advances","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal co-IP identifying condensin II as binding partner, Hi-C genome-wide validation of chromosome organization changes, 3D imaging confirmation; single lab","pmids":["31131328"],"is_preprint":false},{"year":2019,"finding":"ARID1A and PI3K pathway mutations cooperate in the endometrial epithelium: ARID1A is normally bound to promoters with open chromatin to repress EMT genes; ARID1A loss increases promoter chromatin accessibility and EMT gene expression; PI3K activation partially rescues mesenchymal phenotypes through antagonism of ARID1A target genes, resulting in partial EMT and collective invasion.","method":"Mouse conditional knockout (monoallelic ARID1A loss + PI3K activation), ATAC-seq, ChIP-seq, transcriptomics, invasion assays","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo mouse model combined with genome-wide ATAC-seq and ChIP-seq; epistasis between ARID1A and PI3K established; multiple orthogonal methods","pmids":["31391455"],"is_preprint":false},{"year":2019,"finding":"Inflammatory IKKβ signaling phosphorylates ARID1A, leading to its degradation via β-TRCP; ARID1A loss in turn silences the enhancer of A20 deubiquitinase (a NF-κB negative regulator), unleashing CXCR2 ligand-mediated PMN-MDSC chemotaxis and creating an immunosuppressive tumor microenvironment.","method":"Prostate-specific conditional Arid1a knockout mouse model, co-immunoprecipitation, ChIP-seq, MDSC neutralization experiments, Western blot for IKKβ/β-TRCP/ARID1A axis","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo genetic model, phosphorylation/degradation mechanism established biochemically, chromatin mechanism for A20 repression shown by ChIP-seq, rescued by MDSC neutralization","pmids":["36435834"],"is_preprint":false},{"year":2019,"finding":"Arid1a deficiency in hepatocytes impairs fatty acid oxidation by downregulating PPARα and altering the epigenetic landscape of metabolic genes, increasing susceptibility to hepatic steatosis and insulin resistance under high-fat diet conditions.","method":"Hepatocyte-specific Arid1a knockout mice, glucose/insulin tolerance tests, ChIP, RNA-seq, ATAC-seq, isolated primary hepatocytes","journal":"EBioMedicine","confidence":"High","confidence_rationale":"Tier 2 / Moderate — in vivo conditional KO with metabolic phenotype, ChIP and ATAC-seq mechanistic data; multiple orthogonal methods, single lab","pmids":["30879920"],"is_preprint":false},{"year":2020,"finding":"ARID1A inactivation increases SWI/SNF complex targeting to genomic sites of luminal lineage-determining transcription factors (ER, FOXA1, GATA3), disrupts ER-FOXA1 chromatin interactions and ER-dependent transcription, and drives a switch from ER-dependent luminal to ER-independent basal-like cell identity, conferring resistance to ER degraders.","method":"CRISPR-Cas9 epigenome screen, ARID1A inactivation in cells and patient samples, ChIP-seq, ATAC-seq, gene expression profiling","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — genome-wide CRISPR screen plus ChIP-seq/ATAC-seq mechanistic validation; patient sample corroboration; multiple orthogonal methods","pmids":["31932695"],"is_preprint":false},{"year":2020,"finding":"ARID1A acts as a transcriptional repressor at ER cis-regulatory elements in a FOXA1-dependent manner; deletion of ARID1A causes loss of HDAC1 binding, increased H4 lysine acetylation, and subsequent BRD4-driven transcription and cell growth, explaining sensitivity to BET inhibitors upon ARID1A loss.","method":"CRISPR genome-wide screen, ChIP-seq, ATAC-seq, HDAC1 co-occupancy analysis, pharmacological BET inhibition","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — genome-wide CRISPR screen identifies ARID1A, ChIP-seq confirms HDAC1 loss and H4Kac gain at specific loci, mechanistic link to BRD4-driven transcription established","pmids":["31913353"],"is_preprint":false},{"year":2020,"finding":"TRIM32 (E3 ubiquitin ligase) promotes ARID1A degradation via the ubiquitin-proteasome system in squamous cell carcinoma, while USP11 (deubiquitinase) stabilizes ARID1A; the TRIM32/USP11-ARID1A-SDC2 axis controls SCC proliferation and metastasis.","method":"Co-immunoprecipitation, ubiquitination assays, siRNA/shRNA knockdown, CRISPR KO, rescue experiments, in vivo tumor models","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Moderate — biochemical identification of E3 ligase (TRIM32) and DUB (USP11) with ubiquitination assay validation, rescue experiments; multiple orthogonal methods, single lab","pmids":["31914402"],"is_preprint":false},{"year":2020,"finding":"ARID1A cooperates with transcription factor CEBPα to repress UCA1 lncRNA transcription in breast cancer by regulating chromatin access at the UCA1 locus; ARID1A loss derepresses UCA1 and mediates increased cell proliferation and migration.","method":"siRNA knockdown, ChIP for histone modifications and ARID1A occupancy, luciferase reporter assay, rescue experiments with UCA1","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP demonstrates direct locus occupancy with histone modification changes, CEBPα cooperativity shown, UCA1 rescue validates downstream effector; single lab","pmids":["29980791"],"is_preprint":false},{"year":2021,"finding":"ARID1A loss leads to R-loop accumulation and transcription-replication conflicts; ARID1A binds ATR and TOP2A, and its loss reduces TOP2A binding at R-loop sites, implicating ARID1A in resolution of replication stress through chromatin regulation.","method":"ARID1A knockout cell lines, R-loop detection (S9.6 immunofluorescence/DRIP-seq), DNA fiber assays for replication dynamics, ChIP for TOP2A","journal":"PLoS genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ARID1A KO with R-loop and replication dynamics phenotype, TOP2A ChIP mechanistic link; single lab, multiple orthogonal methods","pmids":["33826602"],"is_preprint":false},{"year":2021,"finding":"ARID1A inactivation upregulates glutaminase (GLS1) because SWI/SNF normally represses GLS1; ARID1A loss shifts glucose metabolism toward glutamine-dependent TCA cycle and aspartate synthesis, creating a specific vulnerability to GLS1 inhibition.","method":"ARID1A knockout, metabolic flux analysis, ChIP-seq for SWI/SNF at GLS1 locus, orthotopic and patient-derived xenograft models, GLS1 inhibitor (CB-839) treatment","journal":"Nature cancer","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP-seq establishes SWI/SNF repression of GLS1, metabolic flux validates dependence, in vivo PDX confirmation; multiple orthogonal methods","pmids":["34085048"],"is_preprint":false},{"year":2021,"finding":"ARID1A directly represses p53 pathway genes (including ATF3) in the endometrial epithelium in vivo; co-existing ARID1A and TP53 mutations promote invasive adenocarcinoma through ATF3 induction, reduced apoptosis, and TP63+ squamous differentiation.","method":"Genetically engineered mouse models (ARID1A/PIK3CA and TP53/PIK3CA conditional knockouts), ChIP-seq, transcriptome profiling, histopathological analysis","journal":"PLoS genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo genetic epistasis established by mouse models, ChIP-seq shows direct ARID1A occupancy at p53 target gene loci, transcriptomic comparison across genotypes","pmids":["34941867"],"is_preprint":false},{"year":2021,"finding":"ARID1A loss activates MAPK signaling by downregulating the phosphatase DUSP4; ARID1A normally maintains histone acetylation (H3K27Ac, H3K9Ac) at DUSP4 regulatory regions; DUSP4 re-expression or MAPK pathway inhibition mitigates tumor formation in vivo.","method":"RNA-seq in isogenic ARID1A-null vs wild-type cells, ChIP-seq for histone marks at DUSP4 locus, DUSP4 rescue experiments, in vivo pharmacological MAPK inhibition","journal":"Journal of biomedical science","confidence":"High","confidence_rationale":"Tier 2 / Moderate — RNA-seq plus ChIP-seq establish epigenetic mechanism, DUSP4 rescue and in vivo pharmacological validation; multiple orthogonal methods, single lab","pmids":["38071325"],"is_preprint":false},{"year":2021,"finding":"ARID1A physically interacts with progesterone receptor isoform PGR-A (but not PGR-B) in mouse and human endometrium; ARID1A loss reduces PgR enhancer accessibility (H3K27Ac, BRG1 signals) and decreases PR expression in endometrial epithelial neoplasia.","method":"Co-immunoprecipitation, proximity ligation assay, ChIP-seq for ARID1A/BRG1/H3K27Ac at PgR enhancer, immunohistochemistry in human and mouse (Pten/Arid1a KO) tissues","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — physical interaction confirmed by two orthogonal methods (co-IP and PLA), ChIP-seq shows mechanistic link to PgR enhancer, in vivo mouse model corroboration","pmids":["33706098","36853791"],"is_preprint":false},{"year":2021,"finding":"ARID1A loss activates mTOR signaling (increased pS6) and SOX9 nuclear expression in gastric adenocarcinoma cells and mouse gastric epithelial cells; mTOR inhibitor (RAD001) can curtail this activation, establishing an ARID1A-mTOR-SOX9 axis.","method":"ARID1A knockdown in GAC cell lines, CK19-Cre-Arid1a knockout mice, Western blot for pS6/SOX9, in vivo PDX models with mTOR inhibitor","journal":"Gut","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo genetic model plus in vitro knockdown, pharmacological rescue; molecular mechanism upstream of mTOR not fully defined; single lab","pmids":["33785559"],"is_preprint":false},{"year":2021,"finding":"Arid1a loss suppresses TGF-β/Smad4 tumor suppressor signaling in biliary cells; Kras/Arid1a double mutant mice develop cholangiocarcinoma preceded by failed engagement of TGF-β-Smad4 pathway, establishing an ARID1A-TGF-β-Smad4 axis limiting biliary epithelial oncogenic response.","method":"Murine conditional Kras/Arid1a knockout models with biliary and hepatocyte lineage tracing, cell culture proliferation/cell cycle assays, chromatin structure analysis, TGF-β pathway signaling readouts","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo genetic epistasis in mouse model, pathway activity measured biochemically; direct ARID1A occupancy at TGF-β pathway genes not fully shown; single lab","pmids":["36044839"],"is_preprint":false},{"year":2021,"finding":"ARID1A regulates ARID1A target gene SLC7A11 chromatin accessibility and is required for PPARα-driven fatty acid oxidation in hepatocytes, as shown by ATAC-seq and ChIP identifying reduced open chromatin at PPARα target genes upon Arid1a deletion.","method":"Hepatocyte-specific Arid1a KO, ATAC-seq, ChIP, RNA-seq","journal":"EBioMedicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ATAC-seq and ChIP provide mechanistic epigenomic data; single lab, multiple orthogonal methods","pmids":["30879920"],"is_preprint":false},{"year":2022,"finding":"ARID1A recruits HDAC1 via its C-terminal DUF3518 domain to the USP9X promoter, repressing USP9X and downstream AMPK (PRKAA2) activity; ARID1A loss increases H3K9 and H3K27 acetylation at the USP9X promoter and upregulates USP9X-AMPK signaling, enabling tumor cell adaptation to glucose starvation.","method":"CRISPR KO, mass spectrometry for ARID1A-interacting proteins, co-IP, GST pulldown, ChIP, luciferase reporter assay","journal":"Cellular and molecular gastroenterology and hepatology","confidence":"High","confidence_rationale":"Tier 2 / Strong — domain-specific interaction (DUF3518-HDAC1) confirmed by GST pulldown and co-IP, ChIP establishes promoter occupancy, histone modification changes quantified; multiple orthogonal methods","pmids":["35390516"],"is_preprint":false},{"year":2022,"finding":"ARID1A loss in lung cancer increases chromatin accessibility at glycolytic gene promoters (Pgam1, Pkm, Pgk1), reduces HDAC1 recruitment and increases H4 lysine acetylation at these loci, enhancing HIF1α binding and BRD4-driven transcription of glycolytic genes and promoting metabolic reprogramming toward glycolysis.","method":"Genetically engineered mouse models (KP and KPA), ATAC-seq, ChIP-seq, transcriptomics, metabolic flux assays, pharmacological inhibition of glycolysis and BET","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo mouse model, ATAC-seq/ChIP-seq mechanistic validation, metabolic confirmation; multiple orthogonal methods","pmids":["34987057"],"is_preprint":false},{"year":2022,"finding":"ARID1A loss in ARID1A-deficient cells leads to HDAC6-mediated EMT and enhanced invasion; HDAC6 inhibition reverses the migratory and invasive phenotype of ARID1A-knockdown endometrial cancer cells and creates apoptotic vulnerability to etoposide.","method":"siRNA/shRNA knockdown in endometrial cell lines and 3D primary cultures, HDAC6 inhibitor (ACY1215), in vivo mouse metastasis models","journal":"Molecular oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function with defined phenotypic rescue by HDAC6 inhibition, in vivo validation; indirect (no ChIP showing ARID1A directly at HDAC6 locus); single lab","pmids":["35167193"],"is_preprint":false},{"year":2022,"finding":"ARID1A loss induces aberrant DNA methylation (CpG island methylator phenotype, CIMP) at genomic regions with pre-existing or acquired H3K27me3; ARID1A knockout in cultured cells directly causes CIMP, indicating ARID1A normally prevents PRC2-associated DNA hypermethylation.","method":"ARID1A knockout in 293FT and GES1 cells, genome-wide DNA methylation analysis (EPIC array), H3K27me3 ChIP-seq","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct genetic KO with genome-wide DNA methylation profiling correlated with H3K27me3 ChIP-seq; causal relationship established in cell lines; single lab","pmids":["35131383"],"is_preprint":false},{"year":2023,"finding":"ARID1A suppresses postnatal cardiomyocyte proliferation by directly binding and inhibiting YAP and TAZ, preventing their interaction with TEAD; ARID1A also promotes cardiomyocyte maturation by increasing chromatin accessibility for maturation transcription factors. Arid1a inactivation after ischemic injury enhances border zone cardiomyocyte proliferation.","method":"Conditional Arid1a KO in mice, genome-wide transcriptome and epigenome (ATAC-seq), co-immunoprecipitation for ARID1A-YAP/TAZ interaction, cardiac injury model","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo conditional KO, direct protein-protein interaction by co-IP, genome-wide chromatin accessibility data, cardiac injury model validation; multiple orthogonal methods","pmids":["37543677"],"is_preprint":false},{"year":2023,"finding":"SWI/SNF (ARID1A) inactivation downregulates rate-limiting mevalonate pathway enzymes (HMGCR, HMGCS1), creating dependency on residual mevalonate pathway activity; mevalonate pathway inhibitors (statins) suppress ARID1A-mutant tumor growth and synergize with immune checkpoint blockade by promoting inflammasome-regulated pyroptosis.","method":"ARID1A knockout, gene expression analysis showing HMGCR/HMGCS1 downregulation, statin treatment in mouse genetic OCCC model and humanized PDX, anti-PD-L1 combination","journal":"Cancer cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic and pharmacological loss-of-function with in vivo validation; direct ChIP evidence for ARID1A at mevalonate gene loci not fully described in abstract; single lab","pmids":["36963401"],"is_preprint":false},{"year":2023,"finding":"ARID1A loss in HCC represses PKM (glycolysis) expression, shifting glucose metabolism from aerobic glycolysis to TCA cycle dependence, and this creates vulnerability to copper-induced cuproptosis that directly targets the TCA cycle.","method":"CRISPR-Cas9 ARID1A KO, CRISPR synthetic lethality screen, transcriptomics (PKM downregulation), metabolic analysis, copper treatment in cell lines and xenografts","journal":"Cell reports. Medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — CRISPR screen identifies TCA dependency, transcriptomic and metabolic mechanistic validation, in vivo xenograft confirmation; single lab","pmids":["37939712"],"is_preprint":false},{"year":2023,"finding":"ARID1A deficiency causes accumulation of DNA base lesions and abasic (AP) sites due to impaired base excision repair (BER); ARID1A mutations delay recruitment kinetics of long-patch BER effectors; combination of TMZ and PARP inhibitors exploits this BER defect to cause DSBs and replication stress in ARID1A-deficient cells.","method":"ARID1A-deficient cell lines, AP site quantification, BER protein recruitment kinetics (live cell imaging/ChIP), comet assay, in vivo xenograft models","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanistic pathway established (BER defect/AP sites) with recruitment kinetics data, in vivo validation; single lab; specific biochemical BER reconstitution not described","pmids":["37306706"],"is_preprint":false},{"year":2024,"finding":"ARID1A accumulates at DNA double-strand breaks (DSBs) and promotes both NHEJ and HR repair pathways; at DSBs, ARID1A recruits RAD21 and CTCF to form chromatin loops, recruits HDAC1 and RSF1 to silence transcription in active regions, controls histone mark distribution, and reduces RNAPII. ARID1A depletion enhances micronuclei accumulation and activates the cGAS-STING pathway.","method":"ARID1A depletion, DSB induction (ionizing radiation), immunofluorescence at DSBs, ChIP for RAD21/CTCF/HDAC1/RSF1/histone marks, RNAPII ChIP, chromatin conformation assays, cGAS-STING pathway readouts","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple ChIP experiments define mechanism at DSBs, chromatin loop formation validated, downstream cGAS-STING pathway activation confirmed; multiple orthogonal methods","pmids":["38587186"],"is_preprint":false},{"year":2024,"finding":"ARID1A recognizes R-loops with high affinity in an ATM-dependent manner and recruits METTL3/METTL14, which m6A-methylate R-loop RNA; this m6A modification facilitates RNase H1 recruitment to drive R-loop resolution and promote DNA end resection at DSBs.","method":"R-loop binding assays (in vitro and in vivo), co-immunoprecipitation of ARID1A-METTL3/14 complex, m6A modification assays, RNase H1 recruitment ChIP, cell survival upon cytotoxic agent treatment","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — biochemical complex identification plus mechanistic R-loop resolution pathway established; temporal ordering (ARID1A→METTL3/14→m6A→RNase H1) shown; multiple orthogonal methods","pmids":["38358891"],"is_preprint":false},{"year":2024,"finding":"ARID1A orchestrates SWI/SNF-mediated sequential binding of transcription factors PU.1 and NF-κB at cytokine and CD40 signaling genes in germinal center B cells; absence of ARID1A tilts GC cell fate toward immature IgM+CD80-PD-L2- memory B cells. ARID1A mutation induces synthetic lethality to SMARCA2/4 inhibition.","method":"ARID1A conditional knockout in murine B cells, ChIP-seq for TF binding (PU.1, NF-κB), transcriptomics, flow cytometry for B cell populations, SMARCA2/4 inhibitor sensitivity assays","journal":"Cancer cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo conditional KO, ChIP-seq for sequential TF binding, multiple orthogonal methods, patient sample corroboration","pmids":["38458187"],"is_preprint":false},{"year":2024,"finding":"ARID1A harbors a prion-like domain (PrLD) that drives liquid-liquid phase separation (LLPS), forming nuclear condensates enriched at EWS/FLI1 target enhancers in Ewing's sarcoma; ARID1A condensates induce long-range chromatin architectural changes at oncogenic target genes; disruption of ARID1A LLPS reduces proliferative and invasive abilities.","method":"In vitro LLPS assays, immunofluorescence of nuclear condensates, genome-wide chromatin structure profiling (Hi-ChIP/ATAC-seq), PrLD mutagenesis, Ewing's sarcoma patient specimens and cell lines","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro LLPS validation and genome-wide chromatin data in cell lines; functional consequence (proliferation/invasion) upon condensate disruption; PrLD specificity established by mutagenesis; single lab","pmids":["39095374"],"is_preprint":false},{"year":2024,"finding":"ARID1A is required for IRF4 expression in multiple myeloma and functionally associates with IRF4 protein on chromatin; deletion of Arid1a in activated murine B cells disrupts IRF4-dependent transcriptional networks and blocks plasma cell differentiation.","method":"Multi-omics (functional genomics screening, spatial proteomics, ChIP-seq), conditional Arid1a KO in murine B cells, flow cytometry for plasma cell markers, SWI/SNF inhibitor treatment","journal":"Cancer cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP-seq demonstrates ARID1A-IRF4 co-occupancy, in vivo conditional KO blocks plasma cell differentiation, multi-omics approach; multiple orthogonal methods","pmids":["38906156"],"is_preprint":false},{"year":2018,"finding":"ARID1A directly represses MVIH lncRNA transcription in HCC by binding through its ARID domain and C-terminal protein binding domain to the MVIH locus; ARID1A also upregulates CDKN1A (p21) and suppresses HCC cell proliferation and migration through inhibition of MVIH.","method":"Co-immunoprecipitation (ARID1A-MVIH RNA interaction), domain mapping, ChIP, siRNA knockdown, proliferation and migration assays","journal":"Biochemical and biophysical research communications","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, domain mapping is computational/biochemical but lncRNA-protein interaction mechanistic details are limited in abstract; functional data from siRNA","pmids":["28716731"],"is_preprint":false},{"year":2021,"finding":"ARID1A controls trophoblast cell migration and invasion by downregulating Snail transcription (reducing migration) and by binding to and destabilizing MMP-9 protein (reducing invasion); overexpression of ARID1A inhibits JEG-3 cell migration and invasion, while knockdown promotes these processes.","method":"ARID1A overexpression and knockdown in JEG-3 cells, Snail transcription assays, co-immunoprecipitation/co-localization of ARID1A and MMP-9, invasion/migration assays","journal":"Reproductive sciences","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, ARID1A-MMP-9 protein interaction and Snail regulation shown by limited methods; mechanistic detail in abstract is sparse","pmids":["34255312"],"is_preprint":false},{"year":2018,"finding":"The C-terminus of BAF250a contains an ARM-repeat fold; mutagenesis of a conserved valine (V1067G) in the ARID domain destabilizes the domain structure and abolishes DNA binding activity, demonstrating that conserved residues in the ARID are required for structural integrity and DNA interaction.","method":"Comparative sequence analysis, homology modeling, mutagenesis (V1067G), in vitro DNA binding affinity assay, biophysical stability measurements","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro mutagenesis combined with DNA binding assay establishes structure-function relationship; limited to domain-level analysis; single lab","pmids":["30307988"],"is_preprint":false}],"current_model":"ARID1A (BAF250a) is a defining subunit of the mammalian BAF (SWI/SNF) chromatin remodeling complex that uses its non-sequence-specific ARID domain to bind DNA and its C-terminal ARM-repeat domain and DUF3518 domain to recruit chromatin regulators (HDAC1, HDAC3, Brg1, NuRD, condensin II); it maintains open or closed chromatin states at tissue-specific enhancers and promoters, represses EMT, mevalonate pathway, glutaminase, and oncogenic transcription programs while activating lineage-specific and metabolic gene expression (PPARα, STAG1, DUSP4, SLC7A11, PgR), and directly participates in DNA damage repair by accumulating at DSBs to recruit RAD21/CTCF for chromatin loop formation, HDAC1/RSF1 for transcription silencing, and METTL3/METTL14 for m6A-dependent R-loop resolution via RNase H1; its loss is regulated post-translationally by TRIM32/β-TRCP-mediated ubiquitin-proteasome degradation (countered by USP11), and ARID1A protein stability is further modulated by IKKβ phosphorylation and amino acid-induced TRIM21-mediated degradation."},"narrative":{"mechanistic_narrative":"ARID1A (BAF250a/p270) is a defining, isoform-specific subunit of the mammalian SWI/SNF (BAF) chromatin remodeling complex that governs lineage-specific gene expression, genome organization, metabolism, and genome stability [PMID:9584200, PMID:22621927]. Its ARID domain binds DNA without sequence preference, and a conserved valine within the domain is required for both structural integrity and DNA binding [PMID:10757798, PMID:30307988]. Within SWI/SNF, ARID1A directs the catalytic subunit BRG1 to tissue-specific promoters and enhancers to set nucleosome occupancy and chromatin accessibility, repressing bivalent developmental loci and controlling differentiation timing [PMID:22621927, PMID:26070559]; it is essential for early embryonic germ-layer formation and ES-cell self-renewal [PMID:18448678] and for cardiac progenitor, sinoatrial pacemaker, and cardiomyocyte programs, in part by partnering with NuRD, HDAC3, and by directly binding and inhibiting YAP/TAZ [PMID:24335282, PMID:25145359, PMID:37543677]. ARID1A acts largely as a transcriptional repressor by recruiting HDAC1 via its C-terminal DUF3518 domain, with loss leading to histone hyperacetylation and BRD4-driven transcription at target loci [PMID:35390516, PMID:31913353, PMID:34987057]. It is targeted to chromatin through physical interactions with sequence-specific factors including HIC1, FOXA1/ER, progesterone receptor PGR-A, and the B-cell factors PU.1, NF-κB, and IRF4 [PMID:19486893, PMID:31913353, PMID:33706098, PMID:36853791, PMID:38458187, PMID:38906156]. ARID1A maintains genome architecture and stability by partitioning interphase chromosomes through condensin II and by sustaining cohesin subunit STAG1 for telomere cohesion [PMID:31131328, PMID:31492885], and it functions directly in DNA repair: it accumulates at double-strand breaks to recruit RAD21/CTCF for loop formation and HDAC1/RSF1 for transcriptional silencing, and it recognizes R-loops in an ATM-dependent manner to recruit METTL3/METTL14 and RNase H1 for m6A-dependent R-loop resolution [PMID:38587186, PMID:38358891]. ARID1A loss reprograms metabolism and creates therapeutic vulnerabilities, repressing GLS1 and driving glutamine dependence, controlling SLC7A11/glutathione, mevalonate, glycolytic, and PPARα-driven fatty-acid-oxidation programs [PMID:34085048, PMID:30686770, PMID:36963401, PMID:34987057, PMID:30879920]. ARID1A abundance is controlled post-translationally by IKKβ phosphorylation and β-TRCP-, TRIM32-mediated proteasomal degradation, opposed by the deubiquitinase USP11 [PMID:36435834, PMID:31914402].","teleology":[{"year":1998,"claim":"Established that ARID1A is a physical subunit of human SWI/SNF, placing it within the chromatin remodeling machinery rather than acting independently.","evidence":"Immunoprecipitation and protein purification from mammalian cells co-purifying p270 with SWI/SNF subunits","pmids":["9584200"],"confidence":"High","gaps":["Did not define which subcomplex configurations ARID1A occupies","Functional role within the complex not yet addressed"]},{"year":2000,"claim":"Resolved how ARID1A engages DNA, showing its ARID domain binds DNA without sequence specificity and that AT-rich preference is not intrinsic to all ARID domains.","evidence":"In vitro DNA binding assays with purified ARID domain","pmids":["10757798"],"confidence":"High","gaps":["Does not explain how genomic targeting specificity is achieved","Structural basis of non-specific binding not defined"]},{"year":2005,"claim":"Demonstrated an isoform-specific anti-proliferative function, distinguishing ARID1A from its paralog ARID1B in coupling differentiation to cell-cycle arrest.","evidence":"siRNA knockdown with parallel ARID1B control, DNA synthesis and p21/cyclin readouts in a differentiation-inducible system","pmids":["16230384"],"confidence":"High","gaps":["Direct chromatin targets mediating p21 induction not identified","Mechanism of isoform specificity unresolved"]},{"year":2008,"claim":"Showed ARID1A is required in vivo for early development and ES-cell pluripotency, establishing its role in lineage commitment.","evidence":"Conditional mouse knockout with microarray, immunostaining, and embryoid body differentiation assays","pmids":["18448678"],"confidence":"High","gaps":["Direct vs indirect regulation of Sox2/Oct4/Utf1 not separated","Lineage-selective differentiation defects mechanistically incomplete"]},{"year":2009,"claim":"Identified sequence-specific recruitment of ARID1A-SWI/SNF by HIC1 to repress E2F1, explaining how the non-specific ARID domain is targeted to defined loci.","evidence":"Yeast two-hybrid, co-IP, and ChIP-reChIP in fibroblasts and BRG1-null cells","pmids":["19486893"],"confidence":"High","gaps":["Generality of TF-mediated recruitment beyond HIC1 not yet shown","Structural interface with HIC1 undefined"]},{"year":2012,"claim":"Established that ARID1A directs BRG1 recruitment and chromatin accessibility at cardiac progenitor gene promoters in vivo, linking remodeling to organ morphogenesis.","evidence":"Conditional KO, ChIP, and DNase I accessibility in second heart field","pmids":["22621927"],"confidence":"High","gaps":["Cofactors enabling promoter selectivity not identified","Open vs closed state switching not mechanistically resolved here"]},{"year":2013,"claim":"Showed ARID1A cooperates with NuRD to toggle cardiac genes between open and poised states, expanding its repressive cofactor repertoire.","evidence":"Affinity purification-MS, co-IP, ChIP, and RNAi in P19 cells and embryonic heart","pmids":["24335282"],"confidence":"Medium","gaps":["Direct physical contacts with specific NuRD subunits not mapped","Single-lab characterization"]},{"year":2014,"claim":"Defined a transcriptional hierarchy in which ARID1A with Tbx3 and HDAC3 represses Nkx2.5 to maintain pacemaker identity, connecting remodeling to electrophysiological cell fate.","evidence":"SAN-specific conditional KO, time-series transcriptomics, genetic epistasis","pmids":["25145359"],"confidence":"High","gaps":["Direct ARID1A occupancy at Nkx2.5 not shown in this study","HDAC3 recruitment mechanism not detailed"]},{"year":2015,"claim":"Demonstrated ARID1A controls nucleosome occupancy at bivalent developmental promoters and balances BRG1 vs PRC2 (Suz12) recruitment, mechanistically tying it to poised chromatin.","evidence":"Acute conditional deletion with MNase-seq and histone modification ChIP-seq in ES cells","pmids":["26070559"],"confidence":"High","gaps":["Direct ARID1A-PRC2 antagonism mechanism not defined","How nucleosome occupancy is mechanistically set unclear"]},{"year":2019,"claim":"Revealed ARID1A's role in 3D genome architecture, partitioning interphase chromosomes via condensin II and shaping TAD borders and compartments.","evidence":"Co-IP, Hi-C, ChIP-seq, and 3D chromosome painting in ARID1A KO cells","pmids":["31131328"],"confidence":"High","gaps":["Direct condensin II contact site not mapped","Causal link between architecture changes and transcription not fully resolved"]},{"year":2019,"claim":"Explained why ARID1A-mutant tumors lack copy-number alterations, showing ARID1A sustains STAG1 for telomere cohesion and selective elimination of aberrant cells.","evidence":"ARID1A KO, telomere FISH, STAG1 rescue, and cancer genomics correlation","pmids":["31492885"],"confidence":"High","gaps":["Mechanism of STAG1 transcriptional control beyond ChIP not detailed","Relationship to condensin II role unclear"]},{"year":2019,"claim":"Established multiple metabolic and tumor-suppressive transcriptional programs under ARID1A control (SLC7A11/glutathione, PPARα/FAO, EMT genes), defining synthetic-lethal vulnerabilities.","evidence":"ARID1A KO cell and mouse models with ChIP, ATAC-seq, RNA-seq, metabolic and xenograft assays","pmids":["30686770","30879920","31391455","25686104"],"confidence":"High","gaps":["Whether ARID1A directly binds each metabolic locus uniformly not shown","Tissue-specificity of these programs incompletely mapped"]},{"year":2019,"claim":"Identified post-translational control of ARID1A through IKKβ phosphorylation and β-TRCP degradation, linking inflammatory signaling to ARID1A loss and an immunosuppressive microenvironment.","evidence":"Prostate conditional KO, co-IP, ChIP-seq, MDSC neutralization, Western blots of the IKKβ/β-TRCP axis","pmids":["36435834"],"confidence":"High","gaps":["Phosphorylation sites and degron not fully mapped","Generality across tissues not established"]},{"year":2020,"claim":"Showed ARID1A represses ER/FOXA1-driven luminal programs by recruiting HDAC1, with loss causing histone hyperacetylation, BRD4-driven transcription, lineage switching, and BET-inhibitor sensitivity.","evidence":"Genome-wide CRISPR screens with ChIP-seq, ATAC-seq, and pharmacological BET/ER inhibition","pmids":["31932695","31913353"],"confidence":"High","gaps":["Direct ARID1A-FOXA1 interaction interface not defined","How SWI/SNF retargeting after ARID1A loss is controlled unclear"]},{"year":2020,"claim":"Identified opposing ubiquitin machinery (TRIM32 degradation vs USP11 stabilization) governing ARID1A protein levels in squamous carcinoma.","evidence":"Co-IP, ubiquitination assays, knockdown/KO, rescue, and in vivo tumor models","pmids":["31914402"],"confidence":"High","gaps":["Ubiquitination site mapping incomplete","Single-lab characterization of the TRIM32/USP11 axis"]},{"year":2021,"claim":"Extended ARID1A's metabolic repressor role, showing SWI/SNF represses GLS1 and glycolytic genes, with loss creating glutamine and BRD4-dependent vulnerabilities.","evidence":"ARID1A KO with metabolic flux, ChIP-seq, ATAC-seq, and PDX/inhibitor studies","pmids":["34085048","34987057"],"confidence":"High","gaps":["Direct vs indirect repression of all metabolic loci not uniformly shown","Interplay between competing metabolic dependencies unresolved"]},{"year":2021,"claim":"Defined direct repression of p53-pathway and signaling genes (ATF3, DUSP4) and TF partnerships (PGR-A) in epithelial tumorigenesis.","evidence":"Genetically engineered mouse models with ChIP-seq, transcriptomics, co-IP, and PLA","pmids":["34941867","38071325","33706098","36853791"],"confidence":"High","gaps":["Mechanism of co-mutation cooperativity incompletely defined","Direct binding to all implicated loci not uniformly demonstrated"]},{"year":2021,"claim":"Implicated ARID1A in replication-stress tolerance, showing it binds ATR/TOP2A and its loss causes R-loop accumulation and transcription-replication conflicts.","evidence":"ARID1A KO, S9.6/DRIP-seq, DNA fiber, and TOP2A ChIP","pmids":["33826602"],"confidence":"Medium","gaps":["Direct ATR/TOP2A interaction interfaces not mapped","Single-lab; biochemical reconstitution lacking"]},{"year":2022,"claim":"Mapped a domain-specific repressive mechanism, showing the C-terminal DUF3518 domain recruits HDAC1 to silence target promoters such as USP9X.","evidence":"CRISPR KO, MS, co-IP, GST pulldown, ChIP, and luciferase assays","pmids":["35390516"],"confidence":"High","gaps":["Structural basis of DUF3518-HDAC1 contact not solved","Breadth of HDAC1-dependent target set incompletely defined"]},{"year":2022,"claim":"Linked ARID1A loss to epigenetic dysregulation including PRC2-associated DNA hypermethylation (CIMP) and HDAC6-driven EMT/invasion.","evidence":"ARID1A KO with EPIC methylation array, H3K27me3 ChIP-seq, and HDAC6-inhibitor phenotype rescue","pmids":["35131383","35167193"],"confidence":"Medium","gaps":["Causal chain from ARID1A loss to specific methylated loci not fully resolved","HDAC6 regulation shown without direct ARID1A locus occupancy"]},{"year":2023,"claim":"Established ARID1A as a direct restraint on cardiomyocyte proliferation via binding and inhibition of YAP/TAZ, with regenerative implications after injury.","evidence":"Conditional Arid1a KO, ATAC-seq, co-IP for ARID1A-YAP/TAZ, and cardiac injury model","pmids":["37543677"],"confidence":"High","gaps":["Interaction interface with YAP/TAZ not mapped","How chromatin remodeling and direct YAP/TAZ inhibition are coordinated unclear"]},{"year":2023,"claim":"Expanded metabolic rewiring by ARID1A loss to mevalonate and TCA-cycle dependence, defining statin and cuproptosis vulnerabilities.","evidence":"ARID1A KO, gene expression, metabolic analysis, and in vivo statin/copper treatments","pmids":["36963401","37939712"],"confidence":"Medium","gaps":["Direct ChIP evidence at mevalonate/PKM loci not fully shown","Single-lab; mechanism of metabolic shift partly correlative"]},{"year":2024,"claim":"Defined a direct role for ARID1A in DNA double-strand-break repair, organizing chromatin loops (RAD21/CTCF), transcriptional silencing (HDAC1/RSF1), and R-loop resolution (METTL3/14, RNase H1), with loss activating cGAS-STING.","evidence":"ARID1A depletion with IR, immunofluorescence, multiple ChIP experiments, R-loop binding assays, co-IP, and cGAS-STING readouts","pmids":["38587186","38358891"],"confidence":"High","gaps":["Order of NHEJ vs HR commitment by ARID1A not fully resolved","Structural basis of R-loop recognition undefined"]},{"year":2024,"claim":"Demonstrated ARID1A orchestrates sequential TF binding (PU.1, NF-κB, IRF4) in B-cell fate and plasma-cell differentiation, with mutation conferring SMARCA2/4 synthetic lethality.","evidence":"Conditional Arid1a KO in murine B cells, ChIP-seq, multi-omics, flow cytometry, and SWI/SNF inhibitor sensitivity","pmids":["38458187","38906156"],"confidence":"High","gaps":["Direct physical interfaces with each TF not mapped","Generality beyond B-lineage contexts not established"]},{"year":2024,"claim":"Identified a prion-like domain enabling ARID1A liquid-liquid phase separation into nuclear condensates that reshape oncogenic enhancer architecture in Ewing's sarcoma.","evidence":"In vitro LLPS assays, condensate imaging, Hi-ChIP/ATAC-seq, and PrLD mutagenesis","pmids":["39095374"],"confidence":"Medium","gaps":["Physiological generality of LLPS beyond Ewing's sarcoma unknown","Single-lab; in vivo relevance of condensates not established"]},{"year":null,"claim":"How ARID1A's non-sequence-specific ARID domain, prion-like phase separation, diverse TF partnerships, and multiple post-translational degradation routes are integrated to achieve context-specific genomic targeting remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified structural model of full-length ARID1A within SWI/SNF on chromatin","Rules governing which transcriptional partner directs ARID1A to which loci unknown","Quantitative relationship between ARID1A dosage, degradation, and tissue-specific phenotypes undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[1,44]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[5,18,23]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[5,29,39]},{"term_id":"GO:0003723","term_label":"RNA binding","supporting_discovery_ids":[38]},{"term_id":"GO:0042393","term_label":"histone binding","supporting_discovery_ids":[9]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,40]},{"term_id":"GO:0000228","term_label":"nuclear chromosome","supporting_discovery_ids":[9,13,37]}],"pathway":[{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[6,9,29]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[5,18,23]},{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[37,38,36]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[3,6,8]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[22,11,30,16]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[2,12,33]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[10,15,19]}],"complexes":["SWI/SNF (BAF) complex"],"partners":["SMARCA4","HIC1","FOXA1","HDAC1","RAD21","CTCF","METTL3","IRF4"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"O14497","full_name":"AT-rich interactive domain-containing protein 1A","aliases":["B120","BRG1-associated factor 250","BAF250","BRG1-associated factor 250a","BAF250A","Osa homolog 1","hOSA1","SWI-like protein","SWI/SNF complex protein p270","SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin subfamily F member 1","hELD"],"length_aa":2285,"mass_kda":242.0,"function":"Involved in transcriptional activation and repression of select genes by chromatin remodeling (alteration of DNA-nucleosome topology). Component of SWI/SNF chromatin remodeling complexes that carry out key enzymatic activities, changing chromatin structure by altering DNA-histone contacts within a nucleosome in an ATP-dependent manner. Binds DNA non-specifically. Belongs to the neural progenitors-specific chromatin remodeling complex (npBAF complex) and the neuron-specific chromatin remodeling complex (nBAF complex). During neural development a switch from a stem/progenitor to a postmitotic chromatin remodeling mechanism occurs as neurons exit the cell cycle and become committed to their adult state. The transition from proliferating neural stem/progenitor cells to postmitotic neurons requires a switch in subunit composition of the npBAF and nBAF complexes. As neural progenitors exit mitosis and differentiate into neurons, npBAF complexes which contain ACTL6A/BAF53A and PHF10/BAF45A, are exchanged for homologous alternative ACTL6B/BAF53B and DPF1/BAF45B or DPF3/BAF45C subunits in neuron-specific complexes (nBAF). The npBAF complex is essential for the self-renewal/proliferative capacity of the multipotent neural stem cells. The nBAF complex along with CREST plays a role regulating the activity of genes essential for dendrite growth (By similarity)","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/O14497/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ARID1A","classification":"Not Classified","n_dependent_lines":242,"n_total_lines":1208,"dependency_fraction":0.20033112582781457},"opencell":{"profiled":true,"resolved_as":"","ensg_id":"ENSG00000117713","cell_line_id":"CID001668","localizations":[{"compartment":"nucleoplasm","grade":3},{"compartment":"chromatin","grade":2}],"interactors":[{"gene":"ACTL6A","stoichiometry":10.0},{"gene":"SMARCA4","stoichiometry":10.0},{"gene":"SMARCD2","stoichiometry":10.0},{"gene":"SS18","stoichiometry":10.0},{"gene":"DPF2","stoichiometry":10.0},{"gene":"SMARCC2","stoichiometry":10.0},{"gene":"SMARCD1","stoichiometry":10.0},{"gene":"SMARCE1","stoichiometry":10.0},{"gene":"SMARCC1","stoichiometry":10.0},{"gene":"SMARCB1","stoichiometry":10.0}],"url":"https://opencell.sf.czbiohub.org/target/CID001668","total_profiled":1310},"omim":[{"mim_id":"616938","title":"COFFIN-SIRIS SYNDROME 5; CSS5","url":"https://www.omim.org/entry/616938"},{"mim_id":"615619","title":"CHOLANGIOCARCINOMA, SUSCEPTIBILITY TO","url":"https://www.omim.org/entry/615619"},{"mim_id":"614609","title":"COFFIN-SIRIS SYNDROME 4; CSS4","url":"https://www.omim.org/entry/614609"},{"mim_id":"614608","title":"COFFIN-SIRIS SYNDROME 3; CSS3","url":"https://www.omim.org/entry/614608"},{"mim_id":"614607","title":"COFFIN-SIRIS SYNDROME 2; CSS2","url":"https://www.omim.org/entry/614607"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/ARID1A"},"hgnc":{"alias_symbol":["B120","P270","C10rf4","BAF250","BAF250a"],"prev_symbol":["C1orf4","SMARCF1"]},"alphafold":{"accession":"O14497","domains":[{"cath_id":"1.10.150.60","chopping":"1004-1110","consensus_level":"high","plddt":85.3345,"start":1004,"end":1110},{"cath_id":"-","chopping":"1661-1744_1839-1863_1969-2025_2047-2094","consensus_level":"medium","plddt":94.7133,"start":1661,"end":2094},{"cath_id":"1.25.10.10","chopping":"2141-2213_2224-2285","consensus_level":"medium","plddt":92.8357,"start":2141,"end":2285}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O14497","model_url":"https://alphafold.ebi.ac.uk/files/AF-O14497-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O14497-F1-predicted_aligned_error_v6.png","plddt_mean":46.91},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ARID1A","jax_strain_url":"https://www.jax.org/strain/search?query=ARID1A"},"sequence":{"accession":"O14497","fasta_url":"https://rest.uniprot.org/uniprotkb/O14497.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O14497/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O14497"}},"corpus_meta":[{"pmid":"20942669","id":"PMC_20942669","title":"ARID1A mutations in endometriosis-associated ovarian carcinomas.","date":"2010","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/20942669","citation_count":1351,"is_preprint":false},{"pmid":"25686104","id":"PMC_25686104","title":"Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers.","date":"2015","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25686104","citation_count":551,"is_preprint":false},{"pmid":"18448678","id":"PMC_18448678","title":"ES cell pluripotency and germ-layer formation require the SWI/SNF chromatin remodeling component BAF250a.","date":"2008","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/18448678","citation_count":276,"is_preprint":false},{"pmid":"30686770","id":"PMC_30686770","title":"Targeting the Vulnerability of Glutathione Metabolism in ARID1A-Deficient Cancers.","date":"2019","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/30686770","citation_count":240,"is_preprint":false},{"pmid":"24618703","id":"PMC_24618703","title":"The emerging roles of ARID1A in tumor suppression.","date":"2014","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/24618703","citation_count":206,"is_preprint":false},{"pmid":"9024684","id":"PMC_9024684","title":"Identification of protein p270/Tpr as a constitutive component of the nuclear pore complex-attached intranuclear filaments.","date":"1997","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/9024684","citation_count":199,"is_preprint":false},{"pmid":"21590771","id":"PMC_21590771","title":"Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas.","date":"2011","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/21590771","citation_count":193,"is_preprint":false},{"pmid":"31932695","id":"PMC_31932695","title":"ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer.","date":"2020","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/31932695","citation_count":186,"is_preprint":false},{"pmid":"26572704","id":"PMC_26572704","title":"ARID1A gene mutation in ovarian and endometrial cancers (Review).","date":"2015","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/26572704","citation_count":144,"is_preprint":false},{"pmid":"31913353","id":"PMC_31913353","title":"ARID1A influences HDAC1/BRD4 activity, intrinsic proliferative capacity and breast cancer treatment response.","date":"2020","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/31913353","citation_count":143,"is_preprint":false},{"pmid":"34619527","id":"PMC_34619527","title":"Targeting ARID1A mutations in cancer.","date":"2021","source":"Cancer treatment reviews","url":"https://pubmed.ncbi.nlm.nih.gov/34619527","citation_count":141,"is_preprint":false},{"pmid":"24036443","id":"PMC_24036443","title":"ARID1A mutations and PI3K/AKT pathway alterations in endometriosis and endometriosis-associated ovarian carcinomas.","date":"2013","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/24036443","citation_count":135,"is_preprint":false},{"pmid":"16230384","id":"PMC_16230384","title":"The p270 (ARID1A/SMARCF1) subunit of mammalian SWI/SNF-related complexes is essential for normal cell cycle arrest.","date":"2005","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/16230384","citation_count":129,"is_preprint":false},{"pmid":"24979463","id":"PMC_24979463","title":"Loss of ARID1A expression sensitizes cancer cells to PI3K- and AKT-inhibition.","date":"2014","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/24979463","citation_count":126,"is_preprint":false},{"pmid":"29730444","id":"PMC_29730444","title":"ARID1A loss in cancer: Towards a mechanistic understanding.","date":"2018","source":"Pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/29730444","citation_count":119,"is_preprint":false},{"pmid":"31391455","id":"PMC_31391455","title":"ARID1A and PI3-kinase pathway mutations in the endometrium drive epithelial transdifferentiation and collective invasion.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/31391455","citation_count":112,"is_preprint":false},{"pmid":"34085048","id":"PMC_34085048","title":"Targeting glutamine dependence through GLS1 inhibition suppresses ARID1A-inactivated clear cell ovarian carcinoma.","date":"2021","source":"Nature cancer","url":"https://pubmed.ncbi.nlm.nih.gov/34085048","citation_count":108,"is_preprint":false},{"pmid":"10757798","id":"PMC_10757798","title":"The human SWI-SNF complex protein p270 is an ARID family member with non-sequence-specific DNA binding activity.","date":"2000","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/10757798","citation_count":106,"is_preprint":false},{"pmid":"20086098","id":"PMC_20086098","title":"Mammalian SWI/SNF--a subunit BAF250/ARID1 is an E3 ubiquitin ligase that targets histone H2B.","date":"2010","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/20086098","citation_count":94,"is_preprint":false},{"pmid":"36435834","id":"PMC_36435834","title":"ARID1A loss induces polymorphonuclear myeloid-derived suppressor cell chemotaxis and promotes prostate cancer progression.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/36435834","citation_count":92,"is_preprint":false},{"pmid":"29760405","id":"PMC_29760405","title":"ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors.","date":"2018","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/29760405","citation_count":86,"is_preprint":false},{"pmid":"9584200","id":"PMC_9584200","title":"p300/CREB binding protein-related protein p270 is a component of mammalian SWI/SNF complexes.","date":"1998","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/9584200","citation_count":82,"is_preprint":false},{"pmid":"22301703","id":"PMC_22301703","title":"Loss of ARID1A/BAF250a-expression in endometriosis: a biomarker for risk of carcinogenic transformation?","date":"2012","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/22301703","citation_count":78,"is_preprint":false},{"pmid":"36963401","id":"PMC_36963401","title":"Targeting the mevalonate pathway suppresses ARID1A-inactivated cancers by promoting pyroptosis.","date":"2023","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/36963401","citation_count":76,"is_preprint":false},{"pmid":"30025943","id":"PMC_30025943","title":"ARID1A mutant ovarian clear cell carcinoma: A clear target for synthetic lethal strategies.","date":"2018","source":"Biochimica et biophysica acta. Reviews on cancer","url":"https://pubmed.ncbi.nlm.nih.gov/30025943","citation_count":76,"is_preprint":false},{"pmid":"15382044","id":"PMC_15382044","title":"Expression of p270 (ARID1A), a component of human SWI/SNF complexes, in human tumors.","date":"2004","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/15382044","citation_count":74,"is_preprint":false},{"pmid":"36123603","id":"PMC_36123603","title":"Treating ARID1A mutated cancers by harnessing synthetic lethality and DNA damage response.","date":"2022","source":"Journal of biomedical science","url":"https://pubmed.ncbi.nlm.nih.gov/36123603","citation_count":73,"is_preprint":false},{"pmid":"30315093","id":"PMC_30315093","title":"SWI/SNF component ARID1A restrains pancreatic neoplasia formation.","date":"2018","source":"Gut","url":"https://pubmed.ncbi.nlm.nih.gov/30315093","citation_count":71,"is_preprint":false},{"pmid":"22977660","id":"PMC_22977660","title":"Loss of ARID1A/BAF250a expression in ovarian endometriosis and clear cell carcinoma.","date":"2012","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/22977660","citation_count":66,"is_preprint":false},{"pmid":"37939712","id":"PMC_37939712","title":"Targeting the TCA cycle through cuproptosis confers synthetic lethality on ARID1A-deficient hepatocellular carcinoma.","date":"2023","source":"Cell reports. Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37939712","citation_count":65,"is_preprint":false},{"pmid":"33826602","id":"PMC_33826602","title":"ARID1A regulates R-loop associated DNA replication stress.","date":"2021","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/33826602","citation_count":64,"is_preprint":false},{"pmid":"34671561","id":"PMC_34671561","title":"The Role of ARID1A in Tumors: Tumor Initiation or Tumor Suppression?","date":"2021","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34671561","citation_count":63,"is_preprint":false},{"pmid":"22621927","id":"PMC_22621927","title":"SWI/SNF protein component BAF250a regulates cardiac progenitor cell differentiation by modulating chromatin accessibility during second heart field development.","date":"2012","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22621927","citation_count":58,"is_preprint":false},{"pmid":"26125128","id":"PMC_26125128","title":"Potential therapeutic targets in ARID1A-mutated cancers.","date":"2015","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/26125128","citation_count":55,"is_preprint":false},{"pmid":"31492885","id":"PMC_31492885","title":"ARID1A promotes genomic stability through protecting telomere cohesion.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/31492885","citation_count":53,"is_preprint":false},{"pmid":"30879920","id":"PMC_30879920","title":"Arid1a regulates insulin sensitivity and lipid metabolism.","date":"2019","source":"EBioMedicine","url":"https://pubmed.ncbi.nlm.nih.gov/30879920","citation_count":48,"is_preprint":false},{"pmid":"38587186","id":"PMC_38587186","title":"ARID1A regulates DNA repair through chromatin organization and its deficiency triggers DNA damage-mediated anti-tumor immune response.","date":"2024","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/38587186","citation_count":47,"is_preprint":false},{"pmid":"38358891","id":"PMC_38358891","title":"The ARID1A-METTL3-m6A axis ensures effective RNase H1-mediated resolution of R-loops and genome stability.","date":"2024","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/38358891","citation_count":47,"is_preprint":false},{"pmid":"10417210","id":"PMC_10417210","title":"Iron modulates phenotypic variation and phosphorylation of P270 in double-stranded RNA virus-infected Trichomonas vaginalis.","date":"1999","source":"Infection and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/10417210","citation_count":47,"is_preprint":false},{"pmid":"31914402","id":"PMC_31914402","title":"TRIM32/USP11 Balances ARID1A Stability and the Oncogenic/Tumor-Suppressive Status of Squamous Cell Carcinoma.","date":"2020","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/31914402","citation_count":47,"is_preprint":false},{"pmid":"31911080","id":"PMC_31911080","title":"ARID1A deficiency and immune checkpoint blockade therapy: From mechanisms to clinical application.","date":"2020","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/31911080","citation_count":44,"is_preprint":false},{"pmid":"19486893","id":"PMC_19486893","title":"HIC1 interacts with a specific subunit of SWI/SNF complexes, ARID1A/BAF250A.","date":"2009","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/19486893","citation_count":44,"is_preprint":false},{"pmid":"34987057","id":"PMC_34987057","title":"Chromatin Remodeling Induced by ARID1A Loss in Lung Cancer Promotes Glycolysis and Confers JQ1 Vulnerability.","date":"2022","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/34987057","citation_count":43,"is_preprint":false},{"pmid":"36890819","id":"PMC_36890819","title":"ARID1A in cancer: Friend or foe?","date":"2023","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/36890819","citation_count":42,"is_preprint":false},{"pmid":"34272091","id":"PMC_34272091","title":"ARID1A mutation/ARID1A loss is associated with a high immunogenic profile in clear cell ovarian cancer.","date":"2021","source":"Gynecologic oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34272091","citation_count":41,"is_preprint":false},{"pmid":"38458187","id":"PMC_38458187","title":"ARID1A orchestrates SWI/SNF-mediated sequential binding of transcription factors with ARID1A loss driving pre-memory B cell fate and lymphomagenesis.","date":"2024","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/38458187","citation_count":40,"is_preprint":false},{"pmid":"27051059","id":"PMC_27051059","title":"BAF250a Expression in Atypical Endometriosis and Endometriosis-Associated Ovarian Cancer.","date":"2016","source":"International journal of gynecological cancer : official journal of the International Gynecological Cancer Society","url":"https://pubmed.ncbi.nlm.nih.gov/27051059","citation_count":40,"is_preprint":false},{"pmid":"26070559","id":"PMC_26070559","title":"BAF250a Protein Regulates Nucleosome Occupancy and Histone Modifications in Priming Embryonic Stem Cell Differentiation.","date":"2015","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26070559","citation_count":39,"is_preprint":false},{"pmid":"29093822","id":"PMC_29093822","title":"EZH2 inhibition in ARID1A mutated clear cell and endometrioid ovarian and endometrioid endometrial cancers.","date":"2017","source":"Gynecologic oncology research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/29093822","citation_count":37,"is_preprint":false},{"pmid":"31847141","id":"PMC_31847141","title":"HuR Reduces Radiation-Induced DNA Damage by Enhancing Expression of ARID1A.","date":"2019","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/31847141","citation_count":35,"is_preprint":false},{"pmid":"24335282","id":"PMC_24335282","title":"Analysis of the SWI/SNF chromatin-remodeling complex during early heart development and BAF250a repression cardiac gene transcription during P19 cell differentiation.","date":"2013","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/24335282","citation_count":34,"is_preprint":false},{"pmid":"32572156","id":"PMC_32572156","title":"ARID1A mutations and expression loss in non-small cell lung carcinomas: clinicopathologic and molecular analysis.","date":"2020","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/32572156","citation_count":34,"is_preprint":false},{"pmid":"28716731","id":"PMC_28716731","title":"ARID1A represses hepatocellular carcinoma cell proliferation and migration through lncRNA MVIH.","date":"2017","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/28716731","citation_count":34,"is_preprint":false},{"pmid":"33917230","id":"PMC_33917230","title":"Treatment Strategies for ARID1A-Deficient Ovarian Clear Cell Carcinoma.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/33917230","citation_count":33,"is_preprint":false},{"pmid":"33785559","id":"PMC_33785559","title":"Loss of ARID1A activates mTOR signaling and SOX9 in gastric adenocarcinoma-rationale for targeting ARID1A deficiency.","date":"2021","source":"Gut","url":"https://pubmed.ncbi.nlm.nih.gov/33785559","citation_count":33,"is_preprint":false},{"pmid":"31131328","id":"PMC_31131328","title":"ARID1A spatially partitions interphase chromosomes.","date":"2019","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/31131328","citation_count":32,"is_preprint":false},{"pmid":"34941867","id":"PMC_34941867","title":"Co-existing TP53 and ARID1A mutations promote aggressive endometrial tumorigenesis.","date":"2021","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34941867","citation_count":32,"is_preprint":false},{"pmid":"26589513","id":"PMC_26589513","title":"The Clinicopathologic Significance of BAF250a (ARID1A) Expression in Hepatocellular Carcinoma.","date":"2015","source":"Pathology oncology research : POR","url":"https://pubmed.ncbi.nlm.nih.gov/26589513","citation_count":31,"is_preprint":false},{"pmid":"36044839","id":"PMC_36044839","title":"Arid1a mutation suppresses TGF-β signaling and induces cholangiocarcinoma.","date":"2022","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/36044839","citation_count":31,"is_preprint":false},{"pmid":"28937020","id":"PMC_28937020","title":"Unique characteristics of ARID1A mutation and protein level in gastric and colorectal cancer: A meta-analysis.","date":"2017","source":"Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association","url":"https://pubmed.ncbi.nlm.nih.gov/28937020","citation_count":31,"is_preprint":false},{"pmid":"38906156","id":"PMC_38906156","title":"IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma.","date":"2024","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/38906156","citation_count":30,"is_preprint":false},{"pmid":"32791396","id":"PMC_32791396","title":"Effect and biomarker of immune checkpoint blockade therapy for ARID1A deficiency cancers.","date":"2020","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/32791396","citation_count":30,"is_preprint":false},{"pmid":"35390516","id":"PMC_35390516","title":"Targeting USP9X-AMPK Axis in ARID1A-Deficient Hepatocellular Carcinoma.","date":"2022","source":"Cellular and molecular gastroenterology and hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/35390516","citation_count":30,"is_preprint":false},{"pmid":"36369379","id":"PMC_36369379","title":"Somatic ARID1A mutation stratifies patients with gastric cancer to PD-1 blockade and adjuvant chemotherapy.","date":"2022","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/36369379","citation_count":30,"is_preprint":false},{"pmid":"32015157","id":"PMC_32015157","title":"ARID1A Hypermethylation Disrupts Transcriptional Homeostasis to Promote Squamous Cell Carcinoma Progression.","date":"2020","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/32015157","citation_count":30,"is_preprint":false},{"pmid":"26832958","id":"PMC_26832958","title":"(Partial) Loss of BAF250a (ARID1A) in rectovaginal deep-infiltrating endometriosis, endometriomas and involved pelvic sentinel lymph nodes.","date":"2016","source":"Molecular human reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/26832958","citation_count":29,"is_preprint":false},{"pmid":"30747208","id":"PMC_30747208","title":"Expression and significance of EBV, ARID1A and PIK3CA in gastric carcinoma.","date":"2019","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/30747208","citation_count":29,"is_preprint":false},{"pmid":"29980791","id":"PMC_29980791","title":"ARID1A and CEBPα cooperatively inhibit UCA1 transcription in breast cancer.","date":"2018","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/29980791","citation_count":29,"is_preprint":false},{"pmid":"32334542","id":"PMC_32334542","title":"Altered ARID1A expression in colorectal cancer.","date":"2020","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/32334542","citation_count":28,"is_preprint":false},{"pmid":"24557437","id":"PMC_24557437","title":"The clinicopathologic significance of the loss of BAF250a (ARID1A) expression in endometrial carcinoma.","date":"2014","source":"International journal of gynecological cancer : official journal of the International Gynecological Cancer Society","url":"https://pubmed.ncbi.nlm.nih.gov/24557437","citation_count":28,"is_preprint":false},{"pmid":"37543677","id":"PMC_37543677","title":"Cardiomyocyte proliferation is suppressed by ARID1A-mediated YAP inhibition during cardiac maturation.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/37543677","citation_count":28,"is_preprint":false},{"pmid":"25145359","id":"PMC_25145359","title":"Baf250a orchestrates an epigenetic pathway to repress the Nkx2.5-directed contractile cardiomyocyte program in the sinoatrial node.","date":"2014","source":"Cell research","url":"https://pubmed.ncbi.nlm.nih.gov/25145359","citation_count":27,"is_preprint":false},{"pmid":"26826411","id":"PMC_26826411","title":"Various ARID1A expression patterns and their clinical significance in gastric cancers.","date":"2015","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26826411","citation_count":26,"is_preprint":false},{"pmid":"39095374","id":"PMC_39095374","title":"Prion-like domain mediated phase separation of ARID1A promotes oncogenic potential of Ewing's sarcoma.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/39095374","citation_count":25,"is_preprint":false},{"pmid":"38833522","id":"PMC_38833522","title":"Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers.","date":"2024","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/38833522","citation_count":25,"is_preprint":false},{"pmid":"34562292","id":"PMC_34562292","title":"Arid1a regulates neural stem/progenitor cell proliferation and differentiation during cortical development.","date":"2021","source":"Cell proliferation","url":"https://pubmed.ncbi.nlm.nih.gov/34562292","citation_count":25,"is_preprint":false},{"pmid":"18357561","id":"PMC_18357561","title":"Bicarbonate-induced phosphorylation of p270 protein in mouse sperm by cAMP-dependent protein kinase.","date":"2008","source":"Molecular reproduction and development","url":"https://pubmed.ncbi.nlm.nih.gov/18357561","citation_count":24,"is_preprint":false},{"pmid":"35421925","id":"PMC_35421925","title":"Roles of ARID1A variations in colorectal cancer: a collaborative review.","date":"2022","source":"Molecular medicine (Cambridge, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/35421925","citation_count":24,"is_preprint":false},{"pmid":"39652583","id":"PMC_39652583","title":"Targeting Arachidonic Acid Metabolism Enhances Immunotherapy Efficacy in ARID1A-Deficient Colorectal Cancer.","date":"2025","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/39652583","citation_count":23,"is_preprint":false},{"pmid":"32039194","id":"PMC_32039194","title":"SWI/SNF Component BAF250a Coordinates OCT4 and WNT Signaling Pathway to Control Cardiac Lineage Differentiation.","date":"2020","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/32039194","citation_count":23,"is_preprint":false},{"pmid":"34804958","id":"PMC_34804958","title":"ARID1A Mutation in Metastatic Breast Cancer: A Potential Therapeutic Target.","date":"2021","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34804958","citation_count":23,"is_preprint":false},{"pmid":"35131383","id":"PMC_35131383","title":"ARID1A loss-of-function induces CpG island methylator phenotype.","date":"2022","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/35131383","citation_count":23,"is_preprint":false},{"pmid":"36882165","id":"PMC_36882165","title":"ARID1A mutations in cancer development: mechanism and therapy.","date":"2023","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/36882165","citation_count":22,"is_preprint":false},{"pmid":"34843932","id":"PMC_34843932","title":"Methionine and leucine induce ARID1A degradation to promote mTOR expression and milk synthesis in mammary epithelial cells.","date":"2021","source":"The Journal of nutritional biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/34843932","citation_count":20,"is_preprint":false},{"pmid":"34083049","id":"PMC_34083049","title":"Role and potential clinical utility of ARID1A in gastrointestinal malignancy.","date":"2020","source":"Mutation research. Reviews in mutation research","url":"https://pubmed.ncbi.nlm.nih.gov/34083049","citation_count":19,"is_preprint":false},{"pmid":"34255312","id":"PMC_34255312","title":"Role of ARID1A in the Regulation of Human Trophoblast Migration and Invasion.","date":"2021","source":"Reproductive sciences (Thousand Oaks, Calif.)","url":"https://pubmed.ncbi.nlm.nih.gov/34255312","citation_count":19,"is_preprint":false},{"pmid":"25913291","id":"PMC_25913291","title":"ARID1A expression in ovarian clear cell carcinoma with an adenofibromatous component.","date":"2015","source":"Histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/25913291","citation_count":19,"is_preprint":false},{"pmid":"30307988","id":"PMC_30307988","title":"Domain architecture of BAF250a reveals the ARID and ARM-repeat domains with implication in function and assembly of the BAF remodeling complex.","date":"2018","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/30307988","citation_count":18,"is_preprint":false},{"pmid":"28253716","id":"PMC_28253716","title":"ARID1A gene knockdown promotes neuroblastoma migration and invasion.","date":"2017","source":"Neoplasma","url":"https://pubmed.ncbi.nlm.nih.gov/28253716","citation_count":18,"is_preprint":false},{"pmid":"35750014","id":"PMC_35750014","title":"Therapeutic significance of ARID1A mutation in bladder cancer.","date":"2022","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/35750014","citation_count":17,"is_preprint":false},{"pmid":"36853791","id":"PMC_36853791","title":"ARID1A Regulates Progesterone Receptor Expression in Early Endometrial Endometrioid Carcinoma Pathogenesis.","date":"2023","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/36853791","citation_count":17,"is_preprint":false},{"pmid":"37306706","id":"PMC_37306706","title":"Temozolomide Sensitizes ARID1A-Mutated Cancers to PARP Inhibitors.","date":"2023","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/37306706","citation_count":17,"is_preprint":false},{"pmid":"38873993","id":"PMC_38873993","title":"ARID1A restrains EMT and stemness of ovarian cancer cells through the Hippo pathway.","date":"2024","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/38873993","citation_count":17,"is_preprint":false},{"pmid":"31731647","id":"PMC_31731647","title":"Mutation-Driven Signals of ARID1A and PI3K Pathways in Ovarian Carcinomas: Alteration Is An Opportunity.","date":"2019","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31731647","citation_count":17,"is_preprint":false},{"pmid":"38071325","id":"PMC_38071325","title":"ARID1A loss activates MAPK signaling via DUSP4 downregulation.","date":"2023","source":"Journal of biomedical science","url":"https://pubmed.ncbi.nlm.nih.gov/38071325","citation_count":17,"is_preprint":false},{"pmid":"33706098","id":"PMC_33706098","title":"ARID1A and PGR proteins interact in the endometrium and reveal a positive correlation in endometriosis.","date":"2021","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/33706098","citation_count":17,"is_preprint":false},{"pmid":"38008753","id":"PMC_38008753","title":"The effects of ARID1A mutation in gastric cancer and its significance for treatment.","date":"2023","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/38008753","citation_count":16,"is_preprint":false},{"pmid":"34249744","id":"PMC_34249744","title":"ARID1A Variations in Cholangiocarcinoma: Clinical Significances and Molecular Mechanisms.","date":"2021","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34249744","citation_count":16,"is_preprint":false},{"pmid":"35167193","id":"PMC_35167193","title":"ARID1A-deficient cells require HDAC6 for progression of endometrial carcinoma.","date":"2022","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/35167193","citation_count":16,"is_preprint":false},{"pmid":"35964817","id":"PMC_35964817","title":"Inhibition of Arid1a increases stem/progenitor cell-like properties of liver cancer.","date":"2022","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/35964817","citation_count":15,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":49543,"output_tokens":11679,"usd":0.161907,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":22944,"output_tokens":7374,"usd":0.149535,"stage2_stop_reason":"end_turn"},"total_usd":0.311442,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1998,\n      \"finding\": \"ARID1A (p270) is an integral component of human SWI/SNF chromatin remodeling complexes, co-purifying with SWI/SNF subunits via antibodies raised against p300/CBP.\",\n      \"method\": \"Immunoprecipitation and protein purification from mammalian cells\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal co-purification established complex membership, replicated by subsequent structural and biochemical studies across multiple labs\",\n      \"pmids\": [\"9584200\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"ARID1A (p270) contains an ARID (AT-rich interactive domain) DNA-binding motif but, unlike other ARID family members, shows no sequence-specific DNA binding preference, demonstrating that AT-rich binding is not an intrinsic property of all ARID domains.\",\n      \"method\": \"DNA binding assays (in vitro) with purified ARID domain\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct in vitro biochemical assay with purified protein; negative result (no sequence preference) is mechanistically informative and well-controlled\",\n      \"pmids\": [\"10757798\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"ARID1A (p270) is specifically required for cell cycle arrest upon differentiation induction: siRNA depletion of p270 (but not the related ARID1B) causes continued DNA synthesis, failure to upregulate p21, and failure to downregulate cyclins and E2F-responsive products, demonstrating a distinct anti-proliferative role for p270-containing SWI/SNF complexes.\",\n      \"method\": \"siRNA knockdown, DNA synthesis assay, Western blot for p21 and cyclins in differentiation-inducible cell system\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean loss-of-function with specific cellular phenotype, isoform-specificity established by parallel ARID1B knockdown control, two orthogonal readouts\",\n      \"pmids\": [\"16230384\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"BAF250a (ARID1A) is essential for early mouse embryonic germ-layer formation (mesodermal layer) and embryonic stem cell pluripotency and self-renewal; ablation arrests development at ~E6.5, promotes primitive endoderm differentiation, and impairs cardiomyocyte and adipocyte but not neuron differentiation, correlating with altered expression of Sox2, Utf1, and Oct4.\",\n      \"method\": \"Mouse knockout (conditional ablation), DNA microarray, immunostaining, RNA analysis, embryoid body differentiation assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo genetic knockout with defined developmental phenotype, multiple orthogonal methods confirming molecular mechanism\",\n      \"pmids\": [\"18448678\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"BAF250b (the ARID1B paralog) assembles with elongin C, cullin 2, and Roc1 into an E3 ubiquitin ligase that monoubiquitinates histone H2B at lysine 120 in vitro; RNAi depletion of BAF250 in human cells and mutation of Drosophila osa (its ortholog) reduce global H2B monoubiquitination, adding an enzymatic ubiquitin ligase function to SWI/SNF-A. Note: this study primarily characterizes ARID1B but also implicates BAF250/ARID1 family members in H2B ubiquitination.\",\n      \"method\": \"Immunopurification, in vitro ubiquitination assay, RNAi in human cells, Drosophila genetics\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution of E3 ligase activity toward H2B-K120; primary characterization is ARID1B, but ARID1A family implication is demonstrated by RNAi of shared subunit; single lab\",\n      \"pmids\": [\"20086098\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"ARID1A physically interacts with the tumor suppressor HIC1 in a BRG1-dependent manner; sequential ChIP demonstrated that HIC1 recruits ARID1A-containing SWI/SNF complexes to repress E2F1 transcription in quiescent fibroblasts; HIC1 does not interact with BRM-containing complexes, establishing specificity for ARID1A-SWI/SNF.\",\n      \"method\": \"Yeast two-hybrid, co-immunoprecipitation, sequential ChIP-reChIP in WI38 fibroblasts and BRG1-null SW13 cells\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal co-IP plus ChIP-reChIP functional validation; interaction dependency confirmed in BRG1-null cells; multiple orthogonal methods in single lab\",\n      \"pmids\": [\"19486893\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"BAF250a (ARID1A) regulates cardiac progenitor cell differentiation in the second heart field by binding selectively to target gene promoters (Mef2c, Nkx2.5, Bmp10) and recruiting the catalytic subunit Brg1 to modulate chromatin accessibility; ablation in SHF causes right ventricular trabeculation defects, VSD, persistent truncus arteriosus, and embryonic lethality.\",\n      \"method\": \"Conditional mouse knockout, ChIP, DNase I digestion (chromatin accessibility), ES cell differentiation model, immunostaining\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo conditional KO with defined cardiac phenotype, ChIP demonstrating direct promoter binding and Brg1 recruitment, chromatin accessibility assay; multiple orthogonal methods\",\n      \"pmids\": [\"22621927\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"BAF250a physically interacts with NuRD complex subunits and cooperates with NuRD to repress cardiac gene transcription by switching chromatin between open and poised states; specific depletion of BAF250a in P19 cells causes arrhythmic contracting cardiomyocytes and modulates BRG1 occupancy at cardiac gene loci.\",\n      \"method\": \"Affinity purification coupled to mass spectrometry, co-immunoprecipitation, ChIP, RNA knockdown in P19 cells and embryonic heart\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mass spectrometry-based complex identification plus ChIP functional validation; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"24335282\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Baf250a (ARID1A) maintains sinoatrial node (SAN) pacemaker cell identity by activating Tbx3 expression and, together with Tbx3 and HDAC3, coordinately repressing Nkx2.5; SAN-specific deletion causes sinus bradycardia and sick sinus disease by derepressing Nkx2.5-driven contractile cardiomyocyte gene program.\",\n      \"method\": \"Conditional mouse knockout (SAN-specific), transcriptomic time-series analysis, genetic epistasis\",\n      \"journal\": \"Cell research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo conditional KO with defined arrhythmia phenotype, transcriptional hierarchy established by time-series gene expression, genetic pathway ordering\",\n      \"pmids\": [\"25145359\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"BAF250a (ARID1A) regulates nucleosome occupancy at bivalent (H3K4me3/H3K27me3) promoters of key developmental genes in embryonic stem cells; acute deletion increases nucleosome occupancy at these promoters, reduces H3K27me3 and bivalent gene number, elevates Brg1 but reduces Suz12 recruitment, and disrupts differentiation timing.\",\n      \"method\": \"Acute conditional deletion, genome-wide nucleosome mapping (MNase-seq), histone modification ChIP-seq, gene expression analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — genome-wide nucleosome and histone modification profiling with direct genetic perturbation; multiple orthogonal epigenomic methods in single lab\",\n      \"pmids\": [\"26070559\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"EZH2 inhibition is synthetically lethal in ARID1A-mutated ovarian cancer cells; ARID1A and EZH2 co-occupy and regulate PIK3IP1, a direct target whose upregulation upon EZH2 inhibition suppresses PI3K-AKT signaling and mediates the synthetic lethality; EZH2 inhibition causes in vivo regression of ARID1A-mutated tumors.\",\n      \"method\": \"Cell viability assays, ChIP, gene expression analysis, mouse xenograft models, PI3K-AKT signaling assays\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — mechanistic pathway placement (ARID1A–EZH2–PIK3IP1–PI3K-AKT) with ChIP evidence for co-occupancy, validated in vivo; replicated by subsequent studies\",\n      \"pmids\": [\"25686104\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ARID1A-mediated chromatin remodeling is required for expression of SLC7A11, a cystine transporter; ARID1A deficiency reduces basal glutathione (GSH) levels by impairing SLC7A11 expression, making ARID1A-deficient cells specifically vulnerable to GCLC inhibition through ROS-mediated apoptosis.\",\n      \"method\": \"ARID1A knockout cell lines, glutathione measurement, ROS assays, apoptosis assays, xenograft models, ChIP for SLC7A11 locus\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — loss-of-function with defined metabolic mechanism (SLC7A11-GSH axis), in vivo validation; multiple orthogonal methods\",\n      \"pmids\": [\"30686770\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ARID1A inactivation causes defects in telomere cohesion by reducing expression of cohesin subunit STAG1; this selectively eliminates cells with gross chromosomal aberrations during mitosis, explaining why ARID1A-mutated tumors paradoxically lack copy number alterations.\",\n      \"method\": \"ARID1A knockout, telomere FISH, colony formation assays, ChIP for STAG1 locus, STAG1 rescue experiments, analysis of copy number alterations in cancer genomics data\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic loss-of-function, rescue by STAG1 re-expression, mechanistic link to telomere cohesion established, corroborated by cancer genomics data\",\n      \"pmids\": [\"31492885\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ARID1A spatially partitions interphase chromosomes by interacting with condensin II; ARID1A knockout drives redistribution of condensin II preferentially to enhancers, contributes to B-compartment formation, weakens TAD borders, and increases trans interactions of small chromosomes.\",\n      \"method\": \"Co-immunoprecipitation (SWI/SNF–condensin II interaction), Hi-C, ChIP-seq, 3D interphase chromosome painting, ARID1A knockout cells\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal co-IP identifying condensin II as binding partner, Hi-C genome-wide validation of chromosome organization changes, 3D imaging confirmation; single lab\",\n      \"pmids\": [\"31131328\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ARID1A and PI3K pathway mutations cooperate in the endometrial epithelium: ARID1A is normally bound to promoters with open chromatin to repress EMT genes; ARID1A loss increases promoter chromatin accessibility and EMT gene expression; PI3K activation partially rescues mesenchymal phenotypes through antagonism of ARID1A target genes, resulting in partial EMT and collective invasion.\",\n      \"method\": \"Mouse conditional knockout (monoallelic ARID1A loss + PI3K activation), ATAC-seq, ChIP-seq, transcriptomics, invasion assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo mouse model combined with genome-wide ATAC-seq and ChIP-seq; epistasis between ARID1A and PI3K established; multiple orthogonal methods\",\n      \"pmids\": [\"31391455\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Inflammatory IKKβ signaling phosphorylates ARID1A, leading to its degradation via β-TRCP; ARID1A loss in turn silences the enhancer of A20 deubiquitinase (a NF-κB negative regulator), unleashing CXCR2 ligand-mediated PMN-MDSC chemotaxis and creating an immunosuppressive tumor microenvironment.\",\n      \"method\": \"Prostate-specific conditional Arid1a knockout mouse model, co-immunoprecipitation, ChIP-seq, MDSC neutralization experiments, Western blot for IKKβ/β-TRCP/ARID1A axis\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo genetic model, phosphorylation/degradation mechanism established biochemically, chromatin mechanism for A20 repression shown by ChIP-seq, rescued by MDSC neutralization\",\n      \"pmids\": [\"36435834\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Arid1a deficiency in hepatocytes impairs fatty acid oxidation by downregulating PPARα and altering the epigenetic landscape of metabolic genes, increasing susceptibility to hepatic steatosis and insulin resistance under high-fat diet conditions.\",\n      \"method\": \"Hepatocyte-specific Arid1a knockout mice, glucose/insulin tolerance tests, ChIP, RNA-seq, ATAC-seq, isolated primary hepatocytes\",\n      \"journal\": \"EBioMedicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo conditional KO with metabolic phenotype, ChIP and ATAC-seq mechanistic data; multiple orthogonal methods, single lab\",\n      \"pmids\": [\"30879920\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ARID1A inactivation increases SWI/SNF complex targeting to genomic sites of luminal lineage-determining transcription factors (ER, FOXA1, GATA3), disrupts ER-FOXA1 chromatin interactions and ER-dependent transcription, and drives a switch from ER-dependent luminal to ER-independent basal-like cell identity, conferring resistance to ER degraders.\",\n      \"method\": \"CRISPR-Cas9 epigenome screen, ARID1A inactivation in cells and patient samples, ChIP-seq, ATAC-seq, gene expression profiling\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genome-wide CRISPR screen plus ChIP-seq/ATAC-seq mechanistic validation; patient sample corroboration; multiple orthogonal methods\",\n      \"pmids\": [\"31932695\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ARID1A acts as a transcriptional repressor at ER cis-regulatory elements in a FOXA1-dependent manner; deletion of ARID1A causes loss of HDAC1 binding, increased H4 lysine acetylation, and subsequent BRD4-driven transcription and cell growth, explaining sensitivity to BET inhibitors upon ARID1A loss.\",\n      \"method\": \"CRISPR genome-wide screen, ChIP-seq, ATAC-seq, HDAC1 co-occupancy analysis, pharmacological BET inhibition\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genome-wide CRISPR screen identifies ARID1A, ChIP-seq confirms HDAC1 loss and H4Kac gain at specific loci, mechanistic link to BRD4-driven transcription established\",\n      \"pmids\": [\"31913353\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"TRIM32 (E3 ubiquitin ligase) promotes ARID1A degradation via the ubiquitin-proteasome system in squamous cell carcinoma, while USP11 (deubiquitinase) stabilizes ARID1A; the TRIM32/USP11-ARID1A-SDC2 axis controls SCC proliferation and metastasis.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assays, siRNA/shRNA knockdown, CRISPR KO, rescue experiments, in vivo tumor models\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — biochemical identification of E3 ligase (TRIM32) and DUB (USP11) with ubiquitination assay validation, rescue experiments; multiple orthogonal methods, single lab\",\n      \"pmids\": [\"31914402\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ARID1A cooperates with transcription factor CEBPα to repress UCA1 lncRNA transcription in breast cancer by regulating chromatin access at the UCA1 locus; ARID1A loss derepresses UCA1 and mediates increased cell proliferation and migration.\",\n      \"method\": \"siRNA knockdown, ChIP for histone modifications and ARID1A occupancy, luciferase reporter assay, rescue experiments with UCA1\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP demonstrates direct locus occupancy with histone modification changes, CEBPα cooperativity shown, UCA1 rescue validates downstream effector; single lab\",\n      \"pmids\": [\"29980791\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ARID1A loss leads to R-loop accumulation and transcription-replication conflicts; ARID1A binds ATR and TOP2A, and its loss reduces TOP2A binding at R-loop sites, implicating ARID1A in resolution of replication stress through chromatin regulation.\",\n      \"method\": \"ARID1A knockout cell lines, R-loop detection (S9.6 immunofluorescence/DRIP-seq), DNA fiber assays for replication dynamics, ChIP for TOP2A\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ARID1A KO with R-loop and replication dynamics phenotype, TOP2A ChIP mechanistic link; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"33826602\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ARID1A inactivation upregulates glutaminase (GLS1) because SWI/SNF normally represses GLS1; ARID1A loss shifts glucose metabolism toward glutamine-dependent TCA cycle and aspartate synthesis, creating a specific vulnerability to GLS1 inhibition.\",\n      \"method\": \"ARID1A knockout, metabolic flux analysis, ChIP-seq for SWI/SNF at GLS1 locus, orthotopic and patient-derived xenograft models, GLS1 inhibitor (CB-839) treatment\",\n      \"journal\": \"Nature cancer\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP-seq establishes SWI/SNF repression of GLS1, metabolic flux validates dependence, in vivo PDX confirmation; multiple orthogonal methods\",\n      \"pmids\": [\"34085048\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ARID1A directly represses p53 pathway genes (including ATF3) in the endometrial epithelium in vivo; co-existing ARID1A and TP53 mutations promote invasive adenocarcinoma through ATF3 induction, reduced apoptosis, and TP63+ squamous differentiation.\",\n      \"method\": \"Genetically engineered mouse models (ARID1A/PIK3CA and TP53/PIK3CA conditional knockouts), ChIP-seq, transcriptome profiling, histopathological analysis\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo genetic epistasis established by mouse models, ChIP-seq shows direct ARID1A occupancy at p53 target gene loci, transcriptomic comparison across genotypes\",\n      \"pmids\": [\"34941867\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ARID1A loss activates MAPK signaling by downregulating the phosphatase DUSP4; ARID1A normally maintains histone acetylation (H3K27Ac, H3K9Ac) at DUSP4 regulatory regions; DUSP4 re-expression or MAPK pathway inhibition mitigates tumor formation in vivo.\",\n      \"method\": \"RNA-seq in isogenic ARID1A-null vs wild-type cells, ChIP-seq for histone marks at DUSP4 locus, DUSP4 rescue experiments, in vivo pharmacological MAPK inhibition\",\n      \"journal\": \"Journal of biomedical science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RNA-seq plus ChIP-seq establish epigenetic mechanism, DUSP4 rescue and in vivo pharmacological validation; multiple orthogonal methods, single lab\",\n      \"pmids\": [\"38071325\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ARID1A physically interacts with progesterone receptor isoform PGR-A (but not PGR-B) in mouse and human endometrium; ARID1A loss reduces PgR enhancer accessibility (H3K27Ac, BRG1 signals) and decreases PR expression in endometrial epithelial neoplasia.\",\n      \"method\": \"Co-immunoprecipitation, proximity ligation assay, ChIP-seq for ARID1A/BRG1/H3K27Ac at PgR enhancer, immunohistochemistry in human and mouse (Pten/Arid1a KO) tissues\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — physical interaction confirmed by two orthogonal methods (co-IP and PLA), ChIP-seq shows mechanistic link to PgR enhancer, in vivo mouse model corroboration\",\n      \"pmids\": [\"33706098\", \"36853791\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ARID1A loss activates mTOR signaling (increased pS6) and SOX9 nuclear expression in gastric adenocarcinoma cells and mouse gastric epithelial cells; mTOR inhibitor (RAD001) can curtail this activation, establishing an ARID1A-mTOR-SOX9 axis.\",\n      \"method\": \"ARID1A knockdown in GAC cell lines, CK19-Cre-Arid1a knockout mice, Western blot for pS6/SOX9, in vivo PDX models with mTOR inhibitor\",\n      \"journal\": \"Gut\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo genetic model plus in vitro knockdown, pharmacological rescue; molecular mechanism upstream of mTOR not fully defined; single lab\",\n      \"pmids\": [\"33785559\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Arid1a loss suppresses TGF-β/Smad4 tumor suppressor signaling in biliary cells; Kras/Arid1a double mutant mice develop cholangiocarcinoma preceded by failed engagement of TGF-β-Smad4 pathway, establishing an ARID1A-TGF-β-Smad4 axis limiting biliary epithelial oncogenic response.\",\n      \"method\": \"Murine conditional Kras/Arid1a knockout models with biliary and hepatocyte lineage tracing, cell culture proliferation/cell cycle assays, chromatin structure analysis, TGF-β pathway signaling readouts\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo genetic epistasis in mouse model, pathway activity measured biochemically; direct ARID1A occupancy at TGF-β pathway genes not fully shown; single lab\",\n      \"pmids\": [\"36044839\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ARID1A regulates ARID1A target gene SLC7A11 chromatin accessibility and is required for PPARα-driven fatty acid oxidation in hepatocytes, as shown by ATAC-seq and ChIP identifying reduced open chromatin at PPARα target genes upon Arid1a deletion.\",\n      \"method\": \"Hepatocyte-specific Arid1a KO, ATAC-seq, ChIP, RNA-seq\",\n      \"journal\": \"EBioMedicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ATAC-seq and ChIP provide mechanistic epigenomic data; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"30879920\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ARID1A recruits HDAC1 via its C-terminal DUF3518 domain to the USP9X promoter, repressing USP9X and downstream AMPK (PRKAA2) activity; ARID1A loss increases H3K9 and H3K27 acetylation at the USP9X promoter and upregulates USP9X-AMPK signaling, enabling tumor cell adaptation to glucose starvation.\",\n      \"method\": \"CRISPR KO, mass spectrometry for ARID1A-interacting proteins, co-IP, GST pulldown, ChIP, luciferase reporter assay\",\n      \"journal\": \"Cellular and molecular gastroenterology and hepatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — domain-specific interaction (DUF3518-HDAC1) confirmed by GST pulldown and co-IP, ChIP establishes promoter occupancy, histone modification changes quantified; multiple orthogonal methods\",\n      \"pmids\": [\"35390516\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ARID1A loss in lung cancer increases chromatin accessibility at glycolytic gene promoters (Pgam1, Pkm, Pgk1), reduces HDAC1 recruitment and increases H4 lysine acetylation at these loci, enhancing HIF1α binding and BRD4-driven transcription of glycolytic genes and promoting metabolic reprogramming toward glycolysis.\",\n      \"method\": \"Genetically engineered mouse models (KP and KPA), ATAC-seq, ChIP-seq, transcriptomics, metabolic flux assays, pharmacological inhibition of glycolysis and BET\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo mouse model, ATAC-seq/ChIP-seq mechanistic validation, metabolic confirmation; multiple orthogonal methods\",\n      \"pmids\": [\"34987057\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ARID1A loss in ARID1A-deficient cells leads to HDAC6-mediated EMT and enhanced invasion; HDAC6 inhibition reverses the migratory and invasive phenotype of ARID1A-knockdown endometrial cancer cells and creates apoptotic vulnerability to etoposide.\",\n      \"method\": \"siRNA/shRNA knockdown in endometrial cell lines and 3D primary cultures, HDAC6 inhibitor (ACY1215), in vivo mouse metastasis models\",\n      \"journal\": \"Molecular oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function with defined phenotypic rescue by HDAC6 inhibition, in vivo validation; indirect (no ChIP showing ARID1A directly at HDAC6 locus); single lab\",\n      \"pmids\": [\"35167193\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ARID1A loss induces aberrant DNA methylation (CpG island methylator phenotype, CIMP) at genomic regions with pre-existing or acquired H3K27me3; ARID1A knockout in cultured cells directly causes CIMP, indicating ARID1A normally prevents PRC2-associated DNA hypermethylation.\",\n      \"method\": \"ARID1A knockout in 293FT and GES1 cells, genome-wide DNA methylation analysis (EPIC array), H3K27me3 ChIP-seq\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct genetic KO with genome-wide DNA methylation profiling correlated with H3K27me3 ChIP-seq; causal relationship established in cell lines; single lab\",\n      \"pmids\": [\"35131383\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ARID1A suppresses postnatal cardiomyocyte proliferation by directly binding and inhibiting YAP and TAZ, preventing their interaction with TEAD; ARID1A also promotes cardiomyocyte maturation by increasing chromatin accessibility for maturation transcription factors. Arid1a inactivation after ischemic injury enhances border zone cardiomyocyte proliferation.\",\n      \"method\": \"Conditional Arid1a KO in mice, genome-wide transcriptome and epigenome (ATAC-seq), co-immunoprecipitation for ARID1A-YAP/TAZ interaction, cardiac injury model\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo conditional KO, direct protein-protein interaction by co-IP, genome-wide chromatin accessibility data, cardiac injury model validation; multiple orthogonal methods\",\n      \"pmids\": [\"37543677\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"SWI/SNF (ARID1A) inactivation downregulates rate-limiting mevalonate pathway enzymes (HMGCR, HMGCS1), creating dependency on residual mevalonate pathway activity; mevalonate pathway inhibitors (statins) suppress ARID1A-mutant tumor growth and synergize with immune checkpoint blockade by promoting inflammasome-regulated pyroptosis.\",\n      \"method\": \"ARID1A knockout, gene expression analysis showing HMGCR/HMGCS1 downregulation, statin treatment in mouse genetic OCCC model and humanized PDX, anti-PD-L1 combination\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic and pharmacological loss-of-function with in vivo validation; direct ChIP evidence for ARID1A at mevalonate gene loci not fully described in abstract; single lab\",\n      \"pmids\": [\"36963401\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ARID1A loss in HCC represses PKM (glycolysis) expression, shifting glucose metabolism from aerobic glycolysis to TCA cycle dependence, and this creates vulnerability to copper-induced cuproptosis that directly targets the TCA cycle.\",\n      \"method\": \"CRISPR-Cas9 ARID1A KO, CRISPR synthetic lethality screen, transcriptomics (PKM downregulation), metabolic analysis, copper treatment in cell lines and xenografts\",\n      \"journal\": \"Cell reports. Medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CRISPR screen identifies TCA dependency, transcriptomic and metabolic mechanistic validation, in vivo xenograft confirmation; single lab\",\n      \"pmids\": [\"37939712\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ARID1A deficiency causes accumulation of DNA base lesions and abasic (AP) sites due to impaired base excision repair (BER); ARID1A mutations delay recruitment kinetics of long-patch BER effectors; combination of TMZ and PARP inhibitors exploits this BER defect to cause DSBs and replication stress in ARID1A-deficient cells.\",\n      \"method\": \"ARID1A-deficient cell lines, AP site quantification, BER protein recruitment kinetics (live cell imaging/ChIP), comet assay, in vivo xenograft models\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic pathway established (BER defect/AP sites) with recruitment kinetics data, in vivo validation; single lab; specific biochemical BER reconstitution not described\",\n      \"pmids\": [\"37306706\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ARID1A accumulates at DNA double-strand breaks (DSBs) and promotes both NHEJ and HR repair pathways; at DSBs, ARID1A recruits RAD21 and CTCF to form chromatin loops, recruits HDAC1 and RSF1 to silence transcription in active regions, controls histone mark distribution, and reduces RNAPII. ARID1A depletion enhances micronuclei accumulation and activates the cGAS-STING pathway.\",\n      \"method\": \"ARID1A depletion, DSB induction (ionizing radiation), immunofluorescence at DSBs, ChIP for RAD21/CTCF/HDAC1/RSF1/histone marks, RNAPII ChIP, chromatin conformation assays, cGAS-STING pathway readouts\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple ChIP experiments define mechanism at DSBs, chromatin loop formation validated, downstream cGAS-STING pathway activation confirmed; multiple orthogonal methods\",\n      \"pmids\": [\"38587186\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ARID1A recognizes R-loops with high affinity in an ATM-dependent manner and recruits METTL3/METTL14, which m6A-methylate R-loop RNA; this m6A modification facilitates RNase H1 recruitment to drive R-loop resolution and promote DNA end resection at DSBs.\",\n      \"method\": \"R-loop binding assays (in vitro and in vivo), co-immunoprecipitation of ARID1A-METTL3/14 complex, m6A modification assays, RNase H1 recruitment ChIP, cell survival upon cytotoxic agent treatment\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — biochemical complex identification plus mechanistic R-loop resolution pathway established; temporal ordering (ARID1A→METTL3/14→m6A→RNase H1) shown; multiple orthogonal methods\",\n      \"pmids\": [\"38358891\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ARID1A orchestrates SWI/SNF-mediated sequential binding of transcription factors PU.1 and NF-κB at cytokine and CD40 signaling genes in germinal center B cells; absence of ARID1A tilts GC cell fate toward immature IgM+CD80-PD-L2- memory B cells. ARID1A mutation induces synthetic lethality to SMARCA2/4 inhibition.\",\n      \"method\": \"ARID1A conditional knockout in murine B cells, ChIP-seq for TF binding (PU.1, NF-κB), transcriptomics, flow cytometry for B cell populations, SMARCA2/4 inhibitor sensitivity assays\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo conditional KO, ChIP-seq for sequential TF binding, multiple orthogonal methods, patient sample corroboration\",\n      \"pmids\": [\"38458187\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ARID1A harbors a prion-like domain (PrLD) that drives liquid-liquid phase separation (LLPS), forming nuclear condensates enriched at EWS/FLI1 target enhancers in Ewing's sarcoma; ARID1A condensates induce long-range chromatin architectural changes at oncogenic target genes; disruption of ARID1A LLPS reduces proliferative and invasive abilities.\",\n      \"method\": \"In vitro LLPS assays, immunofluorescence of nuclear condensates, genome-wide chromatin structure profiling (Hi-ChIP/ATAC-seq), PrLD mutagenesis, Ewing's sarcoma patient specimens and cell lines\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro LLPS validation and genome-wide chromatin data in cell lines; functional consequence (proliferation/invasion) upon condensate disruption; PrLD specificity established by mutagenesis; single lab\",\n      \"pmids\": [\"39095374\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ARID1A is required for IRF4 expression in multiple myeloma and functionally associates with IRF4 protein on chromatin; deletion of Arid1a in activated murine B cells disrupts IRF4-dependent transcriptional networks and blocks plasma cell differentiation.\",\n      \"method\": \"Multi-omics (functional genomics screening, spatial proteomics, ChIP-seq), conditional Arid1a KO in murine B cells, flow cytometry for plasma cell markers, SWI/SNF inhibitor treatment\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP-seq demonstrates ARID1A-IRF4 co-occupancy, in vivo conditional KO blocks plasma cell differentiation, multi-omics approach; multiple orthogonal methods\",\n      \"pmids\": [\"38906156\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ARID1A directly represses MVIH lncRNA transcription in HCC by binding through its ARID domain and C-terminal protein binding domain to the MVIH locus; ARID1A also upregulates CDKN1A (p21) and suppresses HCC cell proliferation and migration through inhibition of MVIH.\",\n      \"method\": \"Co-immunoprecipitation (ARID1A-MVIH RNA interaction), domain mapping, ChIP, siRNA knockdown, proliferation and migration assays\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, domain mapping is computational/biochemical but lncRNA-protein interaction mechanistic details are limited in abstract; functional data from siRNA\",\n      \"pmids\": [\"28716731\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ARID1A controls trophoblast cell migration and invasion by downregulating Snail transcription (reducing migration) and by binding to and destabilizing MMP-9 protein (reducing invasion); overexpression of ARID1A inhibits JEG-3 cell migration and invasion, while knockdown promotes these processes.\",\n      \"method\": \"ARID1A overexpression and knockdown in JEG-3 cells, Snail transcription assays, co-immunoprecipitation/co-localization of ARID1A and MMP-9, invasion/migration assays\",\n      \"journal\": \"Reproductive sciences\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, ARID1A-MMP-9 protein interaction and Snail regulation shown by limited methods; mechanistic detail in abstract is sparse\",\n      \"pmids\": [\"34255312\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"The C-terminus of BAF250a contains an ARM-repeat fold; mutagenesis of a conserved valine (V1067G) in the ARID domain destabilizes the domain structure and abolishes DNA binding activity, demonstrating that conserved residues in the ARID are required for structural integrity and DNA interaction.\",\n      \"method\": \"Comparative sequence analysis, homology modeling, mutagenesis (V1067G), in vitro DNA binding affinity assay, biophysical stability measurements\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro mutagenesis combined with DNA binding assay establishes structure-function relationship; limited to domain-level analysis; single lab\",\n      \"pmids\": [\"30307988\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ARID1A (BAF250a) is a defining subunit of the mammalian BAF (SWI/SNF) chromatin remodeling complex that uses its non-sequence-specific ARID domain to bind DNA and its C-terminal ARM-repeat domain and DUF3518 domain to recruit chromatin regulators (HDAC1, HDAC3, Brg1, NuRD, condensin II); it maintains open or closed chromatin states at tissue-specific enhancers and promoters, represses EMT, mevalonate pathway, glutaminase, and oncogenic transcription programs while activating lineage-specific and metabolic gene expression (PPARα, STAG1, DUSP4, SLC7A11, PgR), and directly participates in DNA damage repair by accumulating at DSBs to recruit RAD21/CTCF for chromatin loop formation, HDAC1/RSF1 for transcription silencing, and METTL3/METTL14 for m6A-dependent R-loop resolution via RNase H1; its loss is regulated post-translationally by TRIM32/β-TRCP-mediated ubiquitin-proteasome degradation (countered by USP11), and ARID1A protein stability is further modulated by IKKβ phosphorylation and amino acid-induced TRIM21-mediated degradation.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ARID1A (BAF250a/p270) is a defining, isoform-specific subunit of the mammalian SWI/SNF (BAF) chromatin remodeling complex that governs lineage-specific gene expression, genome organization, metabolism, and genome stability [#0, #6]. Its ARID domain binds DNA without sequence preference, and a conserved valine within the domain is required for both structural integrity and DNA binding [#1, #44]. Within SWI/SNF, ARID1A directs the catalytic subunit BRG1 to tissue-specific promoters and enhancers to set nucleosome occupancy and chromatin accessibility, repressing bivalent developmental loci and controlling differentiation timing [#6, #9]; it is essential for early embryonic germ-layer formation and ES-cell self-renewal [#3] and for cardiac progenitor, sinoatrial pacemaker, and cardiomyocyte programs, in part by partnering with NuRD, HDAC3, and by directly binding and inhibiting YAP/TAZ [#7, #8, #33]. ARID1A acts largely as a transcriptional repressor by recruiting HDAC1 via its C-terminal DUF3518 domain, with loss leading to histone hyperacetylation and BRD4-driven transcription at target loci [#29, #18, #30]. It is targeted to chromatin through physical interactions with sequence-specific factors including HIC1, FOXA1/ER, progesterone receptor PGR-A, and the B-cell factors PU.1, NF-\\u03baB, and IRF4 [#5, #18, #25, #39, #41]. ARID1A maintains genome architecture and stability by partitioning interphase chromosomes through condensin II and by sustaining cohesin subunit STAG1 for telomere cohesion [#13, #12], and it functions directly in DNA repair: it accumulates at double-strand breaks to recruit RAD21/CTCF for loop formation and HDAC1/RSF1 for transcriptional silencing, and it recognizes R-loops in an ATM-dependent manner to recruit METTL3/METTL14 and RNase H1 for m6A-dependent R-loop resolution [#37, #38]. ARID1A loss reprograms metabolism and creates therapeutic vulnerabilities, repressing GLS1 and driving glutamine dependence, controlling SLC7A11/glutathione, mevalonate, glycolytic, and PPAR\\u03b1-driven fatty-acid-oxidation programs [#22, #11, #34, #30, #16]. ARID1A abundance is controlled post-translationally by IKK\\u03b2 phosphorylation and \\u03b2-TRCP-, TRIM32-mediated proteasomal degradation, opposed by the deubiquitinase USP11 [#15, #19].\",\n  \"teleology\": [\n    {\n      \"year\": 1998,\n      \"claim\": \"Established that ARID1A is a physical subunit of human SWI/SNF, placing it within the chromatin remodeling machinery rather than acting independently.\",\n      \"evidence\": \"Immunoprecipitation and protein purification from mammalian cells co-purifying p270 with SWI/SNF subunits\",\n      \"pmids\": [\"9584200\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define which subcomplex configurations ARID1A occupies\", \"Functional role within the complex not yet addressed\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Resolved how ARID1A engages DNA, showing its ARID domain binds DNA without sequence specificity and that AT-rich preference is not intrinsic to all ARID domains.\",\n      \"evidence\": \"In vitro DNA binding assays with purified ARID domain\",\n      \"pmids\": [\"10757798\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not explain how genomic targeting specificity is achieved\", \"Structural basis of non-specific binding not defined\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Demonstrated an isoform-specific anti-proliferative function, distinguishing ARID1A from its paralog ARID1B in coupling differentiation to cell-cycle arrest.\",\n      \"evidence\": \"siRNA knockdown with parallel ARID1B control, DNA synthesis and p21/cyclin readouts in a differentiation-inducible system\",\n      \"pmids\": [\"16230384\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct chromatin targets mediating p21 induction not identified\", \"Mechanism of isoform specificity unresolved\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Showed ARID1A is required in vivo for early development and ES-cell pluripotency, establishing its role in lineage commitment.\",\n      \"evidence\": \"Conditional mouse knockout with microarray, immunostaining, and embryoid body differentiation assays\",\n      \"pmids\": [\"18448678\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct vs indirect regulation of Sox2/Oct4/Utf1 not separated\", \"Lineage-selective differentiation defects mechanistically incomplete\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Identified sequence-specific recruitment of ARID1A-SWI/SNF by HIC1 to repress E2F1, explaining how the non-specific ARID domain is targeted to defined loci.\",\n      \"evidence\": \"Yeast two-hybrid, co-IP, and ChIP-reChIP in fibroblasts and BRG1-null cells\",\n      \"pmids\": [\"19486893\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Generality of TF-mediated recruitment beyond HIC1 not yet shown\", \"Structural interface with HIC1 undefined\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Established that ARID1A directs BRG1 recruitment and chromatin accessibility at cardiac progenitor gene promoters in vivo, linking remodeling to organ morphogenesis.\",\n      \"evidence\": \"Conditional KO, ChIP, and DNase I accessibility in second heart field\",\n      \"pmids\": [\"22621927\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cofactors enabling promoter selectivity not identified\", \"Open vs closed state switching not mechanistically resolved here\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Showed ARID1A cooperates with NuRD to toggle cardiac genes between open and poised states, expanding its repressive cofactor repertoire.\",\n      \"evidence\": \"Affinity purification-MS, co-IP, ChIP, and RNAi in P19 cells and embryonic heart\",\n      \"pmids\": [\"24335282\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct physical contacts with specific NuRD subunits not mapped\", \"Single-lab characterization\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Defined a transcriptional hierarchy in which ARID1A with Tbx3 and HDAC3 represses Nkx2.5 to maintain pacemaker identity, connecting remodeling to electrophysiological cell fate.\",\n      \"evidence\": \"SAN-specific conditional KO, time-series transcriptomics, genetic epistasis\",\n      \"pmids\": [\"25145359\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct ARID1A occupancy at Nkx2.5 not shown in this study\", \"HDAC3 recruitment mechanism not detailed\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Demonstrated ARID1A controls nucleosome occupancy at bivalent developmental promoters and balances BRG1 vs PRC2 (Suz12) recruitment, mechanistically tying it to poised chromatin.\",\n      \"evidence\": \"Acute conditional deletion with MNase-seq and histone modification ChIP-seq in ES cells\",\n      \"pmids\": [\"26070559\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct ARID1A-PRC2 antagonism mechanism not defined\", \"How nucleosome occupancy is mechanistically set unclear\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Revealed ARID1A's role in 3D genome architecture, partitioning interphase chromosomes via condensin II and shaping TAD borders and compartments.\",\n      \"evidence\": \"Co-IP, Hi-C, ChIP-seq, and 3D chromosome painting in ARID1A KO cells\",\n      \"pmids\": [\"31131328\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct condensin II contact site not mapped\", \"Causal link between architecture changes and transcription not fully resolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Explained why ARID1A-mutant tumors lack copy-number alterations, showing ARID1A sustains STAG1 for telomere cohesion and selective elimination of aberrant cells.\",\n      \"evidence\": \"ARID1A KO, telomere FISH, STAG1 rescue, and cancer genomics correlation\",\n      \"pmids\": [\"31492885\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of STAG1 transcriptional control beyond ChIP not detailed\", \"Relationship to condensin II role unclear\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Established multiple metabolic and tumor-suppressive transcriptional programs under ARID1A control (SLC7A11/glutathione, PPAR\\u03b1/FAO, EMT genes), defining synthetic-lethal vulnerabilities.\",\n      \"evidence\": \"ARID1A KO cell and mouse models with ChIP, ATAC-seq, RNA-seq, metabolic and xenograft assays\",\n      \"pmids\": [\"30686770\", \"30879920\", \"31391455\", \"25686104\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ARID1A directly binds each metabolic locus uniformly not shown\", \"Tissue-specificity of these programs incompletely mapped\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identified post-translational control of ARID1A through IKK\\u03b2 phosphorylation and \\u03b2-TRCP degradation, linking inflammatory signaling to ARID1A loss and an immunosuppressive microenvironment.\",\n      \"evidence\": \"Prostate conditional KO, co-IP, ChIP-seq, MDSC neutralization, Western blots of the IKK\\u03b2/\\u03b2-TRCP axis\",\n      \"pmids\": [\"36435834\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Phosphorylation sites and degron not fully mapped\", \"Generality across tissues not established\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Showed ARID1A represses ER/FOXA1-driven luminal programs by recruiting HDAC1, with loss causing histone hyperacetylation, BRD4-driven transcription, lineage switching, and BET-inhibitor sensitivity.\",\n      \"evidence\": \"Genome-wide CRISPR screens with ChIP-seq, ATAC-seq, and pharmacological BET/ER inhibition\",\n      \"pmids\": [\"31932695\", \"31913353\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct ARID1A-FOXA1 interaction interface not defined\", \"How SWI/SNF retargeting after ARID1A loss is controlled unclear\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identified opposing ubiquitin machinery (TRIM32 degradation vs USP11 stabilization) governing ARID1A protein levels in squamous carcinoma.\",\n      \"evidence\": \"Co-IP, ubiquitination assays, knockdown/KO, rescue, and in vivo tumor models\",\n      \"pmids\": [\"31914402\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Ubiquitination site mapping incomplete\", \"Single-lab characterization of the TRIM32/USP11 axis\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Extended ARID1A's metabolic repressor role, showing SWI/SNF represses GLS1 and glycolytic genes, with loss creating glutamine and BRD4-dependent vulnerabilities.\",\n      \"evidence\": \"ARID1A KO with metabolic flux, ChIP-seq, ATAC-seq, and PDX/inhibitor studies\",\n      \"pmids\": [\"34085048\", \"34987057\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct vs indirect repression of all metabolic loci not uniformly shown\", \"Interplay between competing metabolic dependencies unresolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Defined direct repression of p53-pathway and signaling genes (ATF3, DUSP4) and TF partnerships (PGR-A) in epithelial tumorigenesis.\",\n      \"evidence\": \"Genetically engineered mouse models with ChIP-seq, transcriptomics, co-IP, and PLA\",\n      \"pmids\": [\"34941867\", \"38071325\", \"33706098\", \"36853791\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of co-mutation cooperativity incompletely defined\", \"Direct binding to all implicated loci not uniformly demonstrated\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Implicated ARID1A in replication-stress tolerance, showing it binds ATR/TOP2A and its loss causes R-loop accumulation and transcription-replication conflicts.\",\n      \"evidence\": \"ARID1A KO, S9.6/DRIP-seq, DNA fiber, and TOP2A ChIP\",\n      \"pmids\": [\"33826602\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct ATR/TOP2A interaction interfaces not mapped\", \"Single-lab; biochemical reconstitution lacking\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Mapped a domain-specific repressive mechanism, showing the C-terminal DUF3518 domain recruits HDAC1 to silence target promoters such as USP9X.\",\n      \"evidence\": \"CRISPR KO, MS, co-IP, GST pulldown, ChIP, and luciferase assays\",\n      \"pmids\": [\"35390516\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of DUF3518-HDAC1 contact not solved\", \"Breadth of HDAC1-dependent target set incompletely defined\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Linked ARID1A loss to epigenetic dysregulation including PRC2-associated DNA hypermethylation (CIMP) and HDAC6-driven EMT/invasion.\",\n      \"evidence\": \"ARID1A KO with EPIC methylation array, H3K27me3 ChIP-seq, and HDAC6-inhibitor phenotype rescue\",\n      \"pmids\": [\"35131383\", \"35167193\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Causal chain from ARID1A loss to specific methylated loci not fully resolved\", \"HDAC6 regulation shown without direct ARID1A locus occupancy\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Established ARID1A as a direct restraint on cardiomyocyte proliferation via binding and inhibition of YAP/TAZ, with regenerative implications after injury.\",\n      \"evidence\": \"Conditional Arid1a KO, ATAC-seq, co-IP for ARID1A-YAP/TAZ, and cardiac injury model\",\n      \"pmids\": [\"37543677\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Interaction interface with YAP/TAZ not mapped\", \"How chromatin remodeling and direct YAP/TAZ inhibition are coordinated unclear\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Expanded metabolic rewiring by ARID1A loss to mevalonate and TCA-cycle dependence, defining statin and cuproptosis vulnerabilities.\",\n      \"evidence\": \"ARID1A KO, gene expression, metabolic analysis, and in vivo statin/copper treatments\",\n      \"pmids\": [\"36963401\", \"37939712\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct ChIP evidence at mevalonate/PKM loci not fully shown\", \"Single-lab; mechanism of metabolic shift partly correlative\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Defined a direct role for ARID1A in DNA double-strand-break repair, organizing chromatin loops (RAD21/CTCF), transcriptional silencing (HDAC1/RSF1), and R-loop resolution (METTL3/14, RNase H1), with loss activating cGAS-STING.\",\n      \"evidence\": \"ARID1A depletion with IR, immunofluorescence, multiple ChIP experiments, R-loop binding assays, co-IP, and cGAS-STING readouts\",\n      \"pmids\": [\"38587186\", \"38358891\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Order of NHEJ vs HR commitment by ARID1A not fully resolved\", \"Structural basis of R-loop recognition undefined\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Demonstrated ARID1A orchestrates sequential TF binding (PU.1, NF-\\u03baB, IRF4) in B-cell fate and plasma-cell differentiation, with mutation conferring SMARCA2/4 synthetic lethality.\",\n      \"evidence\": \"Conditional Arid1a KO in murine B cells, ChIP-seq, multi-omics, flow cytometry, and SWI/SNF inhibitor sensitivity\",\n      \"pmids\": [\"38458187\", \"38906156\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct physical interfaces with each TF not mapped\", \"Generality beyond B-lineage contexts not established\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Identified a prion-like domain enabling ARID1A liquid-liquid phase separation into nuclear condensates that reshape oncogenic enhancer architecture in Ewing's sarcoma.\",\n      \"evidence\": \"In vitro LLPS assays, condensate imaging, Hi-ChIP/ATAC-seq, and PrLD mutagenesis\",\n      \"pmids\": [\"39095374\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological generality of LLPS beyond Ewing's sarcoma unknown\", \"Single-lab; in vivo relevance of condensates not established\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How ARID1A's non-sequence-specific ARID domain, prion-like phase separation, diverse TF partnerships, and multiple post-translational degradation routes are integrated to achieve context-specific genomic targeting remains unresolved.\",\n      \"evidence\": null,\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified structural model of full-length ARID1A within SWI/SNF on chromatin\", \"Rules governing which transcriptional partner directs ARID1A to which loci unknown\", \"Quantitative relationship between ARID1A dosage, degradation, and tissue-specific phenotypes undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [1, 44]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [5, 18, 23]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [5, 29, 39]},\n      {\"term_id\": \"GO:0003723\", \"supporting_discovery_ids\": [38]},\n      {\"term_id\": \"GO:0042393\", \"supporting_discovery_ids\": [9]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 40]},\n      {\"term_id\": \"GO:0000228\", \"supporting_discovery_ids\": [9, 13, 37]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [6, 9, 29]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [5, 18, 23]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [37, 38, 36]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [3, 6, 8]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [22, 11, 30, 16]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [2, 12, 33]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [10, 15, 19]}\n    ],\n    \"complexes\": [\"SWI/SNF (BAF) complex\"],\n    \"partners\": [\"SMARCA4\", \"HIC1\", \"FOXA1\", \"HDAC1\", \"RAD21\", \"CTCF\", \"METTL3\", \"IRF4\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}